<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">89017</article-id><article-id pub-id-type="doi">10.7554/eLife.89017</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.89017.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-128548"><name><surname>Pineda</surname><given-names>Jose Mario Bello</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1417-9200</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-117192"><name><surname>Bradley</surname><given-names>Robert K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8046-1063</contrib-id><email>rbradley@fredhutch.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Basic Sciences Division, Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Department of Genome Sciences, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Medical Scientist Training Program, University of Washington</institution></institution-wrap><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Linch</surname><given-names>Mark</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>University College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>06</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP89017</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-06-14"><day>14</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-07-11"><day>11</day><month>07</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.07.10.548412"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-09-01"><day>01</day><month>09</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.89017.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-10"><day>10</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.89017.2"/></event></pub-history><permissions><copyright-statement>© 2023, Pineda and Bradley</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Pineda and Bradley</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-89017-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-89017-figures-v1.pdf"/><abstract><p>Cancer immune evasion contributes to checkpoint immunotherapy failure in many patients with metastatic cancers. The embryonic transcription factor DUX4 was recently characterized as a suppressor of interferon-γ signaling and antigen presentation that is aberrantly expressed in a small subset of primary tumors. Here, we report that <italic>DUX4</italic> expression is a common feature of metastatic tumors, with ~10–50% of advanced bladder, breast, kidney, prostate, and skin cancers expressing <italic>DUX4. DUX4</italic> expression is significantly associated with immune cell exclusion and decreased objective response to PD-L1 blockade in a large cohort of urothelial carcinoma patients. <italic>DUX4</italic> expression is a significant predictor of survival even after accounting for tumor mutational burden and other molecular and clinical features in this cohort, with <italic>DUX4</italic> expression associated with a median reduction in survival of over 1 year. Our data motivate future attempts to develop DUX4 as a biomarker and therapeutic target for checkpoint immunotherapy resistance.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Over time cancer patients can become resistant to traditional treatments such as chemotherapy and radiotherapy. In some cases, this can be counteracted by administering a new type of treatment called immune checkpoint inhibition which harnesses a patient’s own immune system to eradicate the tumor. However, a significant proportion of cancers remain resistant, even when these immunotherapy drugs are used. This is potentially caused by tumors reactivating a gene called <italic>DUX4</italic>, which is briefly turned on in the early embryo shortly after fertilization, but suppressed in healthy adults.</p><p>Activation of <italic>DUX4</italic> during the early stages of cancer has been shown to remove the cell surface proteins the immune system uses to recognize tumors. However, it remained unclear whether <italic>DUX4</italic> changes the response to immunotherapy in more advanced cancers which have begun to spread and metastasize to other parts of the body.</p><p>To investigate, Pineda and Bradley analyzed publicly available sequencing data which revealed the genes turned on and off in patients with different types of cancer. The analysis showed that <italic>DUX4</italic> is reactivated in approximately 10–50% of advanced bladder, breast, kidney, prostate and skin cancers.</p><p>Next, Pineda and Bradley studied a cohort of patients with advanced bladder cancer who had been treated with immune checkpoint inhibitors. They found that patients with tumors in which <italic>DUX4</italic> had been turned back on had shorter survival times than patients who had not reactivated the gene.</p><p>These results suggest that the activity of <italic>DUX4</italic> could be used to predict which patients with advanced bladder cancer may benefit from immune checkpoint inhibitors<bold>.</bold> In the future, this work could be extended to see if <italic>DUX4</italic> could be used as a prognostic tool for other types of cancer. Future studies could also investigate if the<italic> DUX4</italic> gene could be a therapeutic target for mitigating resistance to immunotherapy in metastatic cancers.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>DUX4</kwd><kwd>immune checkpoint inhibition</kwd><kwd>antigen presentation</kwd><kwd>metastatic cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA251138</award-id><principal-award-recipient><name><surname>Bradley</surname><given-names>Robert K</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01 HL128239</award-id><principal-award-recipient><name><surname>Bradley</surname><given-names>Robert K</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01 HL151651</award-id><principal-award-recipient><name><surname>Bradley</surname><given-names>Robert K</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005189</institution-id><institution>The Leukemia &amp; Lymphoma Society</institution></institution-wrap></funding-source><award-id>1344-18</award-id><principal-award-recipient><name><surname>Bradley</surname><given-names>Robert K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>DUX4</italic> expression is a common feature of metastatic tumors, where it is significantly associated with immune cell exclusion, decreased objective response to immune checkpoint blockade, and reduced patient survival.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Immune checkpoint inhibition (ICI) therapy utilizes immunomodulatory monoclonal antibodies to stimulate patient anti-tumor immune responses. Blockade of T cell co-inhibitory receptors, such as CTLA-4 and the PD-1/PD-L1 axis, has achieved major success in the treatment of diverse metastatic cancers compared to first-line chemotherapy (<xref ref-type="bibr" rid="bib23">Doki et al., 2022</xref>; <xref ref-type="bibr" rid="bib37">Hellmann et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Klein et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Larkin et al., 2019</xref>; <xref ref-type="bibr" rid="bib79">Motzer et al., 2020</xref>; <xref ref-type="bibr" rid="bib108">Stein et al., 2022</xref>). However, a majority of advanced cancer patients fail to respond to ICI due to de novo or acquired resistance, the mechanistic bases of which remain incompletely understood.</p><p>Diverse mechanisms modulate sensitivity and resistance to ICI (<xref ref-type="bibr" rid="bib52">Kalbasi and Ribas, 2020</xref>). These mechanisms include defects in Major Histocompatibility Complex (MHC) class I-mediated antigen presentation due to loss of <italic>B2M</italic> or <italic>HLA</italic> (<xref ref-type="bibr" rid="bib32">Grasso et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">McGranahan et al., 2016</xref>; <xref ref-type="bibr" rid="bib96">Sade-Feldman et al., 2017</xref>; <xref ref-type="bibr" rid="bib110">Sucker et al., 2014</xref>; <xref ref-type="bibr" rid="bib122">Wolf et al., 2019</xref>), <italic>PTEN</italic> and <italic>LSD1</italic> inactivation, which sensitizes tumor cells to type I interferon signaling (<xref ref-type="bibr" rid="bib65">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib85">Peng et al., 2016</xref>; <xref ref-type="bibr" rid="bib101">Sheng et al., 2018</xref>), T cell dysfunction (<xref ref-type="bibr" rid="bib50">Jiang et al., 2018</xref>), presence of specific T cell populations in the tumor microenvironment (<xref ref-type="bibr" rid="bib28">Gide et al., 2019</xref>), and active WNT–β-catenin signaling (<xref ref-type="bibr" rid="bib105">Spranger et al., 2015</xref>). Mitogen-activated protein kinase (MAPK) signaling in <italic>BRAF</italic>-mutated melanomas and CDK4/CDK6 activity have also been implicated in reduced ICI efficacy, and combination treatment with an MAPK/CDK inhibitor improves response to checkpoint blockade (<xref ref-type="bibr" rid="bib4">Ascierto et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Deng et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Ebert et al., 2016</xref>; <xref ref-type="bibr" rid="bib30">Goel et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Jerby-Arnon et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Ribas et al., 2019</xref>; <xref ref-type="bibr" rid="bib97">Schaer et al., 2018</xref>; <xref ref-type="bibr" rid="bib113">Sullivan et al., 2019</xref>).</p><p>Tumor cell-intrinsic interferon-gamma (IFN-γ) signaling is particularly important in anti-tumor immunity. This pathway induces expression of genes involved in MHC class I-mediated antigen processing and presentation, which include genes encoding the TAP1/TAP2 transporters, components of the immunoproteasome, HLA proteins, and B2M (<xref ref-type="bibr" rid="bib1">Alspach et al., 2019</xref>). Thus, suppression of IFN-γ activity promotes tumor immune evasion and decreased CD8<sup>+</sup> T cell activation. Indeed, decreased ICI efficacy was observed in patients with tumors harboring inactivating mutations in IFN-γ pathway genes such as <italic>JAK1</italic> and <italic>JAK2</italic> (<xref ref-type="bibr" rid="bib27">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Nguyen et al., 2021</xref>; <xref ref-type="bibr" rid="bib111">Sucker et al., 2017</xref>; <xref ref-type="bibr" rid="bib128">Zaretsky et al., 2016</xref>). Similarly, a recent study reported a splicing-augmenting mutation in <italic>JAK3</italic>, linked to decreased <italic>JAK3</italic> expression levels, as a potential mechanism of resistance in a patient with metastatic melanoma treated with anti-PD-1 and anti-CTLA-4 combination therapy (<xref ref-type="bibr" rid="bib81">Newell et al., 2022</xref>).</p><p>Some cancers exhibit aberrant expression of embryonic DUX transcription factors. For instance, <italic>DUXB</italic> is expressed in diverse primary malignancies, most notably in testicular germ cell and breast carcinomas (<xref ref-type="bibr" rid="bib87">Preussner et al., 2018</xref>). Recent work from our group and others showed that <italic>DUX4</italic> is expressed in a small subset of primary tumors, where it suppresses tumor cell antigen presentation and response to IFN-γ signaling (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Spens et al., 2023</xref>). We additionally observed signals that <italic>DUX4</italic> expression was associated with reduced survival following response to anti-CTLA-4 or anti-PD-1 in melanoma; however, those analyses relied upon two small cohorts (<italic>n</italic> = 27 or 41 patients), limiting the statistical power of our conclusions.</p><p>In its native embryonic context, DUX4 initializes human zygotic genome activation. <italic>DUX4</italic> expression levels peak at the 4-cell stage of the cleavage embryo; <italic>DUX4</italic> is then immediately silenced via epigenetic repression of the D4Z4 repeat array that contains the <italic>DUX4</italic> gene (<xref ref-type="bibr" rid="bib19">De Iaco et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Hendrickson et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Himeda and Jones, 2019</xref>; <xref ref-type="bibr" rid="bib112">Sugie et al., 2020</xref>; <xref ref-type="bibr" rid="bib119">Whiddon et al., 2017</xref>). Aside from select sites of immune privilege such as the testis, <italic>DUX4</italic> remains silenced in adult somatic tissues (<xref ref-type="bibr" rid="bib18">Das and Chadwick, 2016</xref>; <xref ref-type="bibr" rid="bib103">Snider et al., 2010</xref>).</p><p>Since <italic>DUX4</italic> expression in cancer cells suppresses MHC class I-mediated antigen presentation (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>), we hypothesized that <italic>DUX4</italic> expression might be particularly common in the setting of metastatic disease (vs. the primary cancers that we studied previously), where immune evasion is particularly important. We therefore analyzed several large cohorts of patients with different metastatic cancers to determine the frequency of <italic>DUX4</italic> expression in advanced disease. We additionally rigorously tested the potential importance of <italic>DUX4</italic> expression for patient response to ICI in a well-powered cohort.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>DUX4</italic> is commonly expressed in diverse metastatic cancer types</title><p>To assess the prevalence of <italic>DUX4</italic>-expressing human malignancies, we performed a large-scale analysis of publicly available RNA-seq data across diverse cancer types (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). The majority of the cohorts in The Cancer Genome Atlas (TCGA) are most commonly comprised of primary samples and local metastases. We found that <italic>DUX4</italic> expression is a particularly common feature across advanced-stage cancers, with 10–50% of cancer samples (depending upon cancer type) displaying <italic>DUX4</italic> expression levels comparable to or greater than those observed in the early embryo, where expression of the highly stereotyped DUX4-induced gene expression program is observed (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Hendrickson et al., 2017</xref>). A markedly higher proportion of advanced metastatic cancers express <italic>DUX4</italic>—and tend to have higher absolute <italic>DUX4</italic> expression levels—than do their TCGA cancer counterparts (<xref ref-type="fig" rid="fig1">Figure 1B,C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>DUX4</italic> is frequently expressed in diverse metastatic cancers.</title><p>(<bold>A</bold>) Matched The Cancer Genome Atlas (gray, TCGA) and advanced metastatic (orange) cancer datasets analyzed in our study. (<bold>B</bold>) The proportion of <italic>DUX4</italic>-expressing cancers in TCGA (purple shading) and metastatic (red shading) cancers. The blue line indicates the median over TCGA cancer cohorts. The 95% confidence intervals were estimated via a two-sided proportion test. (<bold>C</bold>) <italic>DUX4</italic> expression values (TPM, transcripts per million) in TCGA (purple shading) and advanced metastatic (red shading) cancer cohorts analyzed in our study. (<bold>D</bold>) Representative RNA-seq coverage plots from primary and metastatic cancers for reads mapping to the <italic>DUX4</italic> cDNA. Open reading frame (ORF, black rectangle); UTR (untranslated region, gray line); homeobox domains (yellow rectangles).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The <italic>DUX4</italic> transcript is likely polyadenylated.</title><p>(<bold>A</bold>) As in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, but The Cancer Genome Atlas (TCGA) cancer cohorts without matched advanced metastatic counterparts analyzed in our study are shown. (<bold>B</bold>) A comparison of <italic>DUX4</italic> expression values (TPM, transcripts per million) measured from sequencing libraries prepared via poly(A) capture or hybrid capture. (<bold>C</bold>) As in (<bold>B</bold>), but a heatmap where patient samples (columns) were stratified according to the indicated categories of <italic>DUX4</italic> expression.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig1-figsupp1-v1.tif"/></fig></fig-group><p>We sought to determine if the <italic>DUX4</italic> transcripts in metastatic cancers express the entire coding sequence or only a portion thereof, as expressed <italic>DUX4</italic> truncations due to genomic rearrangements are frequent oncogenic drivers in particular cancer subtypes, most notably undifferentiated round cell sarcomas (CIC-DUX4 oncoprotein) (<xref ref-type="bibr" rid="bib3">Antonescu et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Choi et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Graham et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Italiano et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Kawamura-Saito et al., 2006</xref>; <xref ref-type="bibr" rid="bib125">Yoshida et al., 2016</xref>; <xref ref-type="bibr" rid="bib126">Yoshimoto et al., 2009</xref>) and adolescent B-cell acute lymphoblastic leukemia (ALL) (<xref ref-type="bibr" rid="bib66">Lilljebjörn et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Qian et al., 2017</xref>; <xref ref-type="bibr" rid="bib124">Yasuda et al., 2016</xref>). We aligned RNA-seq reads to the <italic>DUX4</italic> cDNA sequence and examined read coverage over the open reading frame. Resembling the cleavage stage embryo and <italic>DUX4</italic>-expressing primary cancers, <italic>DUX4</italic>-positive metastatic tumors transcribe the full-length coding region. In contrast, B-cell ALL exhibited the expected C-terminal truncation due to <italic>DUX4</italic> fusion with the <italic>IGH</italic> locus (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><p>Since <italic>DUX4</italic> is typically silent in most healthy tissue contexts outside the cleavage-stage embryo (<xref ref-type="bibr" rid="bib18">Das and Chadwick, 2016</xref>; <xref ref-type="bibr" rid="bib103">Snider et al., 2010</xref>), we investigated if artifacts related to sequencing and sample processing could account for the observed high rates of <italic>DUX4</italic> expression in metastatic vs. primary cancers. We were particularly interested in determining whether the method of RNA recovery influenced <italic>DUX4</italic> detection rate, as the analyzed metastatic cohorts frequently relied upon formalin-fixed samples rather than the frozen samples frequently used by TCGA. We took advantage of a cohort of patients with diverse metastatic tumor types for which patient-matched flash-frozen and formalin-fixed metastatic tumor samples were analyzed by RNA-seq (via poly(A)-selection and hybrid probe capture sequencing library preparations, respectively) (<xref ref-type="bibr" rid="bib92">Robinson et al., 2017</xref>). Our re-analysis revealed that <italic>DUX4</italic> expression is readily detectable and quantifiable for both sample and library preparation methods. <italic>DUX4</italic> transcript levels in the majority of the sequenced samples were higher in poly(A)-selected sequencing than were the analogous measurements obtained from hybrid capture (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,C</xref>). These data demonstrate that the high rates of <italic>DUX4</italic> expression that we observed across metastatic cancer cohorts reflect true <italic>DUX4</italic> expression rather than technical biases introduced by studying formalin-fixed tissues and are consistent with expression of a polyadenylated <italic>DUX4</italic> transcript in both primary and metastatic cancers.</p></sec><sec id="s2-2"><title><italic>DUX4</italic> expression is associated with immune cell exclusion</title><p>We next sought to assess the downstream consequences of <italic>DUX4</italic> expression in metastatic cancers. We focused on urothelial cancers for two reasons. First, urothelial cancers exhibited one of the highest frequencies of <italic>DUX4</italic> expression (54% of patients) in any of the five metastatic cancer cohorts that we analyzed, suggesting that DUX4 could be particularly important in that tumor type. Second, pretreatment samples from 347 patients enrolled in the IMvigor210 trial, a phase 2 trial of anti-PD-L1 (atezolizumab) therapy with advanced urothelial carcinoma, were subject to transcriptome profiling by RNA-seq as well as immunohistochemical analysis, enabling us to conduct comprehensive studies of the association between <italic>DUX4</italic> expression, the global transcriptome, and immunophenotypes in a well-powered cohort (<xref ref-type="bibr" rid="bib6">Balar et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Mariathasan et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Rosenberg et al., 2016</xref>).</p><p>We examined associations between global gene expression profiles and <italic>DUX4</italic> expression in this advanced urothelial carcinoma cohort. We performed differential gene expression analyses on the individuals stratified according to tumor <italic>DUX4</italic> expression status. Gene Ontology (GO) network analyses on the upregulated genes in <italic>DUX4</italic>-positive cancers identified multiple clusters of development-associated terms, consistent with the known role of <italic>DUX4</italic> in early embryogenesis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib19">De Iaco et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Hendrickson et al., 2017</xref>; <xref ref-type="bibr" rid="bib112">Sugie et al., 2020</xref>; <xref ref-type="bibr" rid="bib119">Whiddon et al., 2017</xref>). In contrast, we found a single network associated with downregulated genes: GO terms corresponding to humoral or cell-mediated immunity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Using an IFN-γ gene signature predictive of response to blockade of the PD-1/PD-L1 axis, we found that <italic>DUX4</italic>-expressing cancers have statistically lower levels of IFN-γ activity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib5">Ayers et al., 2017</xref>). Consistent with IFN-γ suppression, we observed extensive downregulation of genes involved in anti-tumor immunity such as those involved in MHC class I-dependent antigen presentation and T cell activation, checkpoint proteins, and chemokines involved in effector T cell recruitment. <italic>DUX4</italic>-expression was also correlated with suppression of genes critical for MHC class II-mediated antigen presentation, namely: MHC class II isotypes (<italic>HLA–DP/DQ/DR</italic>), <italic>HLA-DM</italic>, and <italic>HLA-DO</italic>, and the invariant chain (<italic>CD74</italic>) (<xref ref-type="bibr" rid="bib93">Roche and Furuta, 2015</xref>). MHC class II gene expression is regulated by the transactivator CIITA via a conserved SXY-module present in the promoter regions of these genes. <italic>CIITA</italic> is induced by IFN-γ and is also conspicuously downregulated in <italic>DUX4</italic>-expressing tumors (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="bibr" rid="bib29">Glimcher and Kara, 1992</xref>; <xref ref-type="bibr" rid="bib73">Masternak et al., 2000</xref>; <xref ref-type="bibr" rid="bib106">Steimle et al., 1993</xref>; <xref ref-type="bibr" rid="bib107">Steimle et al., 1994</xref>). MHC class II-mediated antigen presentation can regulate T cell abundance in the tumor microenvironment and patient response to PD-1 blockade (<xref ref-type="bibr" rid="bib51">Johnson et al., 2020</xref>). These analyses suggest that <italic>DUX4</italic> expression in the metastatic context induces an immunosuppressive gene expression program, concordant with its established function in inhibiting JAK–STAT signaling in primary cancers (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>DUX4</italic> expression in advanced cancers is associated with signatures of host anti-tumor immunity inhibition.</title><p>(<bold>A</bold>) Gene Ontology (GO) enrichment network analysis of <italic>DUX4</italic>-downregulated genes. Differentially expressed genes were identified from the comparison of advanced urothelial carcinoma tumors with high (&gt;1 TPM) vs. low (≤1 TPM) <italic>DUX4</italic> expression. The nodes and node sizes correspond to significantly enriched GO terms (Benjamini–Hochberg-adjusted p-value &lt;0.05) and the number of <italic>DUX4</italic>-downregulated genes in each, respectively. The edges connecting nodes indicate shared genes. (<bold>B</bold>) Downregulated (blue) and upregulated (red) anti-tumor immunity genes in tumors with <italic>DUX4</italic>-positive (&gt;1 TPM) vs. -negative (≤1 TPM) advanced urothelial carcinomas. (<bold>C</bold>) Effector CD8<sup>+</sup> T cell score, defined as the mean of the <italic>z</italic>-score normalized gene expression values in the signature (<xref ref-type="bibr" rid="bib72">Mariathasan et al., 2018</xref>) for <italic>DUX4</italic>+/− tumors. The p-value was estimated via a Mann–Whitney <italic>U</italic> test. (<bold>D</bold>) <italic>CXCL9</italic> expression for <italic>DUX4</italic>+/− tumors. The p-value was estimated via a Mann–Whitney <italic>U</italic> test. (<bold>E</bold>) As in (<bold>D</bold>), but illustrating <italic>CXCL10</italic> expression. (<bold>F</bold>) Proportion of immune phenotypes in <italic>DUX4</italic>+/− cancers. The phenotypes were based on the CD8<sup>+</sup> T cell abundance and degree of tumor infiltration determined by anti-CD8 staining of tumor formalin-fixed paraffin-embedded (FFPE) sections in the original study (<xref ref-type="bibr" rid="bib72">Mariathasan et al., 2018</xref>). The p-value was estimated via a multinomial proportion test. (<bold>G</bold>) PD-L1 expression on tumor cells stratified by <italic>DUX4</italic> expression status measured by immunohistochemistry in the original study. The samples were categorized based on the percentage of PD-L1-positive tumor cells. The p-value was estimated via a multinomial proportion test. (<bold>H</bold>) As in (<bold>G</bold>), but PD-L1 staining on tumor-infiltrating immune cells (lymphocytes, macrophages, and dendritic cells) is represented.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title><italic>DUX4</italic> positivity is correlated with an embryonic gene expression signature, downregulation of interferon-gamma (IFN-γ) signaling, and exclusion of diverse immune cell types.</title><p>(<bold>A</bold>) As in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, but the Gene Ontology (GO) enrichment network analysis corresponding to <italic>DUX4</italic>-upregulated genes, compared against the set of coding genes, is shown. (<bold>B</bold>) IFN-γ signature score (<xref ref-type="bibr" rid="bib5">Ayers et al., 2017</xref>). The p-value was estimated via a Mann–Whitney <italic>U</italic> test. (<bold>C</bold>) CD8 T cell score from <xref ref-type="bibr" rid="bib17">Danaher et al., 2017</xref>. The p-value was estimated via a Mann–Whitney <italic>U</italic> test. (<bold>D</bold>) As in (<bold>C</bold>), showing the other immune cell signatures available in <xref ref-type="bibr" rid="bib17">Danaher et al., 2017</xref>. (<bold>E</bold>) Chemokine signature score (<xref ref-type="bibr" rid="bib15">Coppola et al., 2011</xref>). The p-value was estimated via a Mann–Whitney <italic>U</italic> test. (<bold>F</bold>) <italic>DUX4</italic> expression (TPM) in inflamed, immune-excluded, and immune-desert tumors. The phenotypes are based on CD8<sup>+</sup> T cell abundance and degree of tumor infiltration determined by anti-CD8 staining of tumor formalin-fixed paraffin-embedded (FFPE) sections in the original study (<xref ref-type="bibr" rid="bib72">Mariathasan et al., 2018</xref>). The p-values were estimated via the Mann–Whitney <italic>U</italic> test. (<bold>G</bold>) <italic>DUX4</italic> expression (TPM) in advanced urothelial carcinoma tumors. The percentage of tumor cells with positive PD-L1 staining are indicated on the <italic>x</italic>-axis. The p-values were estimated via the Mann–Whitney <italic>U</italic> test. (<bold>H</bold>) As in (<bold>G</bold>), but showing the percentage of tumor-infiltrating immune cells (lymphocytes, macrophages, and dendritic cells) with positive PD-L1 staining on the <italic>x</italic>-axis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig2-figsupp1-v1.tif"/></fig></fig-group><p>We hypothesized that <italic>DUX4</italic> expression in these cancers will generate related transcriptomic signals consistent with CD8<sup>+</sup> T cell exclusion from the tumor. We assessed this using an effector CD8<sup>+</sup> T cell transcriptomic signature developed from initial studies of the IMvigor210 phase 2 trial (<xref ref-type="bibr" rid="bib6">Balar et al., 2017</xref>; <xref ref-type="bibr" rid="bib94">Rosenberg et al., 2016</xref>). <italic>DUX4</italic>-expressing cancers had lower measures of the gene signature, consistent with decreased CD8<sup>+</sup> T cell infiltration into the tumor (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). We also investigated the possible effects of <italic>DUX4</italic> expression on the exclusion of other immune cell types using gene signatures developed from TCGA (<xref ref-type="bibr" rid="bib17">Danaher et al., 2017</xref>). In these analyses, we recapitulated the observation of lower CD8<sup>+</sup> T cell signature associated with <italic>DUX4</italic> positivity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). In addition, we observed patterns consistent with widespread immune cell exclusion from the tumor microenvironment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>).</p><p>Defects in chemokine signaling could partially account for the observed <italic>DUX4</italic>-associated decrease in immune gene signature measurements. To test this hypothesis, we examined expression of chemokines involved in immune cell recruitment. In <italic>DUX4</italic>-expressing cancers, we observed lower mRNA levels of <italic>CXCL9</italic> and <italic>CXCL10</italic>, chemokines which recruit T cells to the tumor site (<xref ref-type="fig" rid="fig2">Figure 2D,E</xref>; <xref ref-type="bibr" rid="bib80">Nagarsheth et al., 2017</xref>). Utilizing a chemokine signature associated with host immune response to solid tumors, we observed that <italic>DUX4</italic> expression was correlated with broad reduction in the expression of chemokine signaling genes, beyond T cell-associated signals (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>; <xref ref-type="bibr" rid="bib15">Coppola et al., 2011</xref>).</p><p>We directly assessed the correlation of <italic>DUX4</italic> expression to immune cell exclusion by examining CD8<sup>+</sup> T cell abundance in the tumor microenvironment, measured by immunohistochemistry (IHC) on formalin-fixed paraffin-embedded patient tumor sections. We verified that <italic>DUX4</italic> expression in the advanced urothelial carcinoma tumors was associated with an immune exclusion phenotype: a higher proportion of <italic>DUX4</italic>+ tumors exhibit either an immune-excluded or immune-desert phenotype compared to malignancies where <italic>DUX4</italic> is silent (<xref ref-type="fig" rid="fig2">Figure 2F</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). We similarly examined the correlation of <italic>DUX4</italic> expression status with PD-L1 levels in the tumor and immune compartments quantified via IHC. We determined that <italic>DUX4</italic> expression was associated with a significant decrease in PD-L1 levels on both tumor and host immune cells, consistent with <italic>DUX4</italic>-induced suppression of IFN-γ signaling (<xref ref-type="fig" rid="fig2">Figure 2G,H</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G,H</xref>). PD-L1 expression on immune cells such as dendritic cells and macrophages modulate anti-tumor immune suppression and response to ICI in in vivo mouse models (<xref ref-type="bibr" rid="bib61">Lau et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Lin et al., 2018</xref>; <xref ref-type="bibr" rid="bib83">Noguchi et al., 2017</xref>). Importantly, PD-L1 levels on immune cells are correlated with response to ICI in clinical trials (<xref ref-type="bibr" rid="bib86">Powles et al., 2014</xref>; <xref ref-type="bibr" rid="bib94">Rosenberg et al., 2016</xref>).</p></sec><sec id="s2-3"><title>DUX4 expression is correlated with poor response to ICI in advanced urothelial carcinoma</title><p>Given the correlation between cancer <italic>DUX4</italic> expression and signatures of anti-tumor immune response suppression, we sought to understand if <italic>DUX4</italic> expression in patient tumors was associated with accompanying changes to overall survival during PD-L1 inhibition. <italic>DUX4</italic> expression was associated with a significant decrease in objective response rates, assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). As expected, higher tumor mutational burden (TMB) was linked to improved survival outcomes in this cohort (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Interestingly, we found that <italic>DUX4</italic> expression was correlated with statistically lower survival rates in this cohort after crudely adjusting for the effects of TMB by removing the bottom quartile of patients, those with the lowest number of missense mutations in their tumors (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Those results motivated us to more carefully control for the effects of other patient covariates in order to better clarify the effects of <italic>DUX4</italic> expression on survival.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>DUX4</italic> positivity is associated with decreased response to immune checkpoint inhibition.</title><p>(<bold>A</bold>) The proportion of clinical response classifications (RECIST, Response Evaluation Criteria in Solid Tumors) in <italic>DUX4</italic>-positive (<italic>DUX4</italic>+, &gt;1 TPM) or -negative (<italic>DUX4−</italic>, ≤1 TPM) advanced urothelial carcinoma patients. RECIST categories were assigned in the original study (<xref ref-type="bibr" rid="bib72">Mariathasan et al., 2018</xref>). The p-value was estimated via a multinomial proportion test. (<bold>B</bold>) Kaplan–Meier (KM) estimates of overall survival for the patients in (<bold>A</bold>) stratified by tumor mutational burden (TMB, number of missense mutations). The estimated survival functions (solid lines), censored events (crosses), and 95% confidence intervals (transparent ribbons) for the patients in the top and bottom TMB quartiles are plotted. The p-value was estimated via a log-rank test. (<bold>C</bold>) As in (<bold>B</bold>), but patients are stratified by <italic>DUX4</italic> expression. To control for possible confounding by TMB, the quartile of patients with the lowest TMB was excluded.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>DUX4</italic> expression status stratifies patients according to survival.</title><p>(<bold>A</bold>) Kaplan–Meier (KM) estimates of overall survival (solid lines), 95% confidence intervals (transparent ribbons), and censored events (crosses) for immune checkpoint inhibition (ICI)-treated advanced urothelial carcinoma patients stratified by <italic>DUX4</italic> expression status. The p-value was estimated via a log-rank test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Risk assignments are improved with <italic>DUX4</italic> expression</title><p>We next determined whether <italic>DUX4</italic> expression was a significant predictor of survival for ICI-treated patients after controlling for TMB and other potentially relevant variables in a statistically rigorous manner. We used Cox Proportional Hazards (PH) regression to quantify the effects of multiple clinical, demographic, and molecular features on risk of death during ICI. For these and subsequent analyses, we elected to define <italic>DUX4</italic>-negative samples as those with <italic>DUX4</italic> expression levels &lt;0.25 TPM. This scheme excludes 126 patients but presumably produces more reliable categorizations, avoiding potential misclassifications due to loss of sensitivity of bulk RNA-seq at very low expression levels (<xref ref-type="bibr" rid="bib78">Mortazavi et al., 2008</xref>). In the context of multivariate Cox PH regression, which controls for the confounding effects of all other covariates simultaneously, we observed that TMB was positively associated with survival [hazard ratio (HR) = 0.14], as expected. Conversely, <italic>DUX4</italic> expression, Eastern Cooperative Oncology Group Performance Status (ECOG PS) &gt;0, and previous administration of platinum chemotherapy were correlated with increased risk (or shorter survival), while other features that have previously been reported as associated with reduced survival e.g., <italic>TGFB1</italic> expression (<xref ref-type="bibr" rid="bib72">Mariathasan et al., 2018</xref>) did not remain significant after controlling for TMB and other variables. In particular, <italic>DUX4</italic> positivity was associated with dramatically worse survival, with a 3.2-fold increase in risk of death at any point in time compared to <italic>DUX4</italic>-negative status (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>DUX4</italic> expression status affects clinical response after controlling for other genetic and clinical variables.</title><p>(<bold>A</bold>) Hazard ratios (HRs) and 95% confidence intervals for the variables included in univariate (left) or multivariate (right) Cox Proportional Hazards (PH) regression. For categorical variables, the reference groups are indicated by points at HR = 1. Statistically significant predictors that are associated with increased (orange) or decreased (blue) risk in both the univariate and multivariate contexts are highlighted. ECOG (Eastern Cooperative Oncology Group); BCG (Bacillus Calmette–Guerin). (<bold>B</bold>) Bayesian information criterion (BIC) measurements for goodness of fit for the full (tumor mutational burden [TMB], Clinical, DUX4 expression) vs. reduced Cox PH models, where lower values indicate better fit. The bootstrapped BIC mean and the 95% confidence interval are illustrated. Clinical (ECOG Performance Status and Platinum treatment history). (<bold>C</bold>) Kaplan–Meier (KM) estimates of overall survival, 95% confidence interval (transparent ribbon), and censored events (crosses) for low-risk (solid gray line) and high-risk (solid orange line) patients in the training (left) and test (right) sets. Risk group assignments were based on risk scores estimated by the full Cox PH model. p-values were estimated via a log-rank test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Cox Proportional Hazards regression models containing <italic>DUX4</italic> expression status as a predictor have a better fit to the data.</title><p>(<bold>A</bold>) Akaike information criterion (AIC) measurements for goodness of fit for the full (tumor mutational burden [TMB], Clinical, DUX4 expression) vs. reduced Cox PH models, where lower values indicate better fit. The bootstrapped AIC mean and the 95% confidence interval are illustrated. Clinical (ECOG Performance Status and Platinum treatment history). (<bold>B</bold>) Harrell’s concordance indices (C-index) for the full (TMB, Clinical, DUX4 expression) vs. reduced Cox PH models, where high values indicate better model performance. The bootstrapped C-index mean and the 95% confidence interval are illustrated. (<bold>C</bold>) Kaplan–Meier (KM) estimates of overall survival, 95% confidence interval (transparent ribbon), and censored events (crosses) for low-risk (solid gray line) and high-risk (solid orange line) patients in the training (left) and test (right) sets. Risk group assignments were based on risk scores estimated by the Cox PH model with only TMB as a predictor. p-values were estimated via a log-rank test. (<bold>D</bold>) As in (<bold>C</bold>), but the risk group assignments were based on risk scores estimated by the Cox PH model with TMB, ECOG Performance Status, and Platinum treatment history as predictors. (<bold>E</bold>) Time-dependent Brier scores for the full and reduced Cox PH models applied on the training (left) and test (right) sets. The Continuous Ranked Probability Scores (CRPS), defined as the integrated Brier score divided by time, are shown in parentheses. Reference refers to the Kaplan–Meier prediction model. A Brier score = 0.25 indicates random guessing (gray dashed line).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We next investigated if <italic>DUX4</italic> expression status carried added value as a predictor over routinely collected clinical and molecular information. We focused on the variables with significant HRs under both the univariate and multivariate regression settings: <italic>DUX4</italic> expression status, TMB, ECOG PS, and history of platinum chemotherapy. We employed goodness-of-fit measurements, which compare the observed data to expectations from Cox PH models created using various combinations of the covariates. In these analyses, we observed a quantifiable improvement in data-model congruence with the addition of <italic>DUX4</italic> expression status (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A,B</xref>). Additionally, we measured statistically significant differences in the likelihoods of the reduced models (without <italic>DUX4</italic> expression as a predictor) when compared to the full model (employs all covariates) (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Taken together, these analyses indicate that <italic>DUX4</italic> expression status is an informative predictor of risk under ICI treatment.</p><p>We evaluated the utility of <italic>DUX4</italic> expression status for pretreatment risk assignment in predicting patient response to ICI. We trained full and reduced Cox PH models on randomly sampled patients (training set, 70% of the cohort) and quantified their respective risk scores. A reference risk score per model was computed as the median score across the training set and was used to ascribe patients into low- vs. high-risk groups. Using these models, we quantified risk scores on the individuals excluded from model construction (test set, 30% of the patients), and similarly assigned patients into low- or high-risk groups based on the training set reference score. By empirically quantifying survival of the two risk groups using KM (Kaplan–Meier) estimation, we found that the full model stratifies patients in an informative manner, appropriately discriminating patients with longer vs. shorter survival times (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C,D</xref>). Furthermore, the addition of <italic>DUX4</italic> expression status improves model performance as illustrated by the time-dependent Brier score, a measure of survival prediction accuracy at specific timepoints (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>).</p></sec><sec id="s2-5"><title><italic>DUX4</italic> expression impedes response to ICI after controlling for other clinical characteristics</title><p>We used a Random Survival Forest (RSF) model to quantify the effect of <italic>DUX4</italic> expression on survival in ICI-treated advanced urothelial carcinoma patients (<xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>). The RSF is a machine learning ensemble, an extension of the Random Forest algorithm for right-censored data (<xref ref-type="bibr" rid="bib10">Breiman, 2001</xref>). It can provide accurate estimates of risk and survival probability at definite times by aggregating predictions from a multitude of base learners (survival trees) (<xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>). RSFs have been successfully used to study time-to-event problems in medicine, including measurement of variable importance (<xref ref-type="bibr" rid="bib21">Dietrich et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Hsich et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Ishwaran et al., 2009</xref>; <xref ref-type="bibr" rid="bib84">O’Brien et al., 2021</xref>; <xref ref-type="bibr" rid="bib99">Semeraro et al., 2011</xref>). We utilized the RSF model to address potential limitations of our Cox PH analyses. First, the RSF model is fully non-parametric and as such does not operate under the Cox PH assumptions: a constant relative hazard between strata over time (PH), a linear relationship between the predictors and the log hazard, and the unspecified baseline hazard function. Second, the RSF model can compute estimates of absolute risk and survival probability over time independent of a reference, unlike relative risk models such as Cox PH (<xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>).</p><p>We used all available molecular, clinical, and demographic covariates to grow an RSF. We randomly selected 70% of the patients to grow the forest, with the resulting model having an out-of-bag (OOB) error of 38.4%. The OOB error stabilizes with increasing number of trees and converges to the leave-one-out cross-validation error estimate. Thus, OOB error is characterized as an unbiased estimate of the model’s true prediction error (<xref ref-type="bibr" rid="bib10">Breiman, 2001</xref>; <xref ref-type="bibr" rid="bib35">Hastie et al., 2009</xref>). In some instances, the OOB error provides overestimates and some reports have recommended treating it as an upper bound (<xref ref-type="bibr" rid="bib11">Bylander, 2002</xref>; <xref ref-type="bibr" rid="bib48">Janitza and Hornung, 2018</xref>; <xref ref-type="bibr" rid="bib76">Mitchell, 2011</xref>). Thus, we measured the RSF model’s test error using a holdout set (the remaining 30% of the cohort) excluded from training. The RSF model recorded a test error of 32.6% illustrating an appropriate fit (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Our error measurements are comparable to <xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>, suggesting our model can be used for inference purposes. Furthermore, the time-dependent Brier score of the RSF model on the training and test sets confirms informative survival prediction (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>).</p><p>The RSF model predicted worse survival outcomes in patients with <italic>DUX4</italic>-expressing cancers compared to their <italic>DUX4</italic>-silent counterparts. These predictions were mirrored in the test dataset, illustrating robustness of the model (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Using time-dependent receiver operating characteristic (ROC) curve analyses, we identified the time range for which the RSF predictive performance is statistically divergent from random guessing: approximately 6–20 months (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). In this window, we observed significant survival differences between patients with <italic>DUX4</italic>+ and <italic>DUX4</italic>− tumors. We highlighted the model’s performance at predicting 1- and 1.5-year survival, typical timepoints of clinical interest. For these times, the RSF appropriately discriminates patient death and survival (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Examining the absolute effects of <italic>DUX4</italic> expression on survival, the RSF model predicted an approximately 20% decrease in both 1- and 1.5-year survival probabilities in patients with <italic>DUX4</italic>-expressing cancers (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Importantly, RSF survival predictions conform closely with the empirical survival estimates obtained via the Kaplan–Meier model (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>DUX4</italic> expression is associated with decreased overall survival in the context of immune checkpoint inhibition.</title><p>(<bold>A</bold>) Random Survival Forest (RSF) predicted overall survival for patients with either <italic>DUX4</italic>-positive or -negative tumors in the training and test sets. Out-of-bag (OOB) survival predictions are shown for the patients in the training set. Survival predictions for individual patients (thin lines) and the median survival function across the cohort (thick line) are represented. <italic>DUX4</italic>− (&lt;0.25 TPM); <italic>DUX4</italic>+ (&gt;1 TPM). (<bold>B</bold>) Training (OOB) and test set survival probability predictions for patients with <italic>DUX4</italic>+/− tumors at 12 and 18 months. The p-values were estimated using a two-sided Mann–Whitney <italic>U</italic> test. (<bold>C</bold>) Survival probability for patients in the training and test sets. Survival functions corresponding to the median RSF prediction (solid orange line) and the Kaplan–Meier estimate (dashed gray) are displayed. (<bold>D</bold>) Feature importance for variables used in the RSF model. The average absolute estimated Shapley values (solid lines) are shown, associated with predicting survival probability at particular times. The 95% confidence interval of the mean (transparent ribbon) is plotted.(<bold>E</bold>) Surface plot showing adjusted (marginal) survival probability, measured via partial dependence, as a function of tumor mutational burden (TMB, number of missense mutations) and time. Each point on the surface corresponds to the mean survival prediction (at the respective timepoint) after TMB is fixed to the respective value for all patients. (<bold>F</bold>) Partial plot showing adjusted survival probability as a function of <italic>DUX4</italic> expression status. The median survival probability (solid lines) and the 95% confidence interval (transparent ribbon) after <italic>DUX4</italic> expression status is fixed to the indicated value for all patients are plotted.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>A Random Survival Forest (RSF) model quantifies the effect of <italic>DUX4</italic> status on overall survival probability in the context of immune checkpoint inhibition.</title><p>(<bold>A</bold>) Error (1 − Harrell’s concordance index) as a function of the number of trees in the RSF model. The training out-of-bag error (OOB error, solid gray line) and the test error (solid orange line) are shown. 1500 trees were used in the final model. (<bold>B</bold>) Time-dependent Brier scores for the RSF model estimated from the training (solid turquoise line) or test (solid teal line) sets. OOB survival predictions were used to calculate the Brier score for the training set. The Continuous Ranked Probability Scores (CRPS), defined as the integrated Brier score divided by time, for both sets are shown. A Brier score = 0.25 indicates random guessing (gray dashed line). (<bold>C</bold>) Time-dependent receiver operating characteristic (ROC) analyses. The cumulative/dynamic area under the ROC curve (AUC<sup>C/D</sup>) (solid orange line) and the 95% confidence interval (transparent orange ribbon) are shown over the observation time for the training and test sets. The OOB mortality predictions were used to calculate the training set AUC<sup>C/D</sup>. (<bold>D</bold>) The ROC curves for the RSF model at 12 (solid turquoise line) and 18 (solid teal line) months. The AUC<sup>C/D</sup> and 95% confidence interval are specified. The OOB mortality predictions were used to calculate the training set AUC<sup>C/D</sup>. (<bold>E</bold>) RSF feature importance. The mean absolute Shapley values and the 95% confidence intervals are shown (left). The standardized permutation importance and confidence regions estimated via delete-<italic>d</italic> jackknife subsampling are plotted (middle); noise variables are indicated by permutation importance measures ≤0. The minimal depth measures are shown (right); variables with values exceeding the depth threshold (gray dashed line) are designated as noise variables. (<bold>F</bold>) Shapley dependence plot illustrating the relationship between tumor mutational burden (TMB, number of missense mutations) and mortality. Each point corresponds to a single patient. (<bold>G</bold>) As in (<bold>F</bold>), but showing <italic>DUX4</italic> expression status. (<bold>H</bold>) Partial plot illustrating the marginal effect of TMB on mortality. Each point corresponds to the average RSF mortality predictions when TMB is fixed to the indicated value for all patients. The transparent ribbon corresponds to the 95% confidence interval. (<bold>I</bold>) Partial plot illustrating the marginal effect of <italic>DUX4</italic> expression status. The points correspond to the RSF prediction for mortality for each patient when <italic>DUX4</italic> expression status is fixed to the indicated value for the entire cohort.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-89017-fig5-figsupp1-v1.tif"/></fig></fig-group><p>We sought to determine the importance of <italic>DUX4</italic> expression status relative to the other covariates in the RSF model. We measured feature importance using estimated Shapley values, which quantify the marginal contribution of each variable to the RSF prediction (<xref ref-type="bibr" rid="bib69">Lundberg and Lee, 2017</xref>; <xref ref-type="bibr" rid="bib71">Maksymiuk et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Shapley, 1953</xref>; <xref ref-type="bibr" rid="bib109">Štrumbelj and Kononenko, 2014</xref>). Specifically, Shapley values measure variable contributions to predictions at the level of each patient. Contributions to the overall performance of the RSF model can be assessed by examining the aggregated summary: the average of the absolute Shapley values for a predictor across the patient cohort. We estimated Shapley values associated with predicting ensemble mortality, the RSF risk estimate. In these analyses, ECOG PS had the largest contribution, followed by TMB and <italic>DUX4</italic> expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). We validated these feature rankings using two independent metrics. The first metric was permutation importance, which quantifies the change in prediction error associated with permutation of a variable’s data; important covariates will record large deviations from the original predictions (<xref ref-type="bibr" rid="bib10">Breiman, 2001</xref>; <xref ref-type="bibr" rid="bib41">Ishwaran, 2007</xref>). The second measure employed was minimal depth, a measure of the variable-node-to-root-node distance within the survival trees of the RSF; important variables tend to have smaller minimal depth values as they are typically used for earlier decision splits (<xref ref-type="bibr" rid="bib44">Ishwaran et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Ishwaran et al., 2011</xref>). Feature contributions measured using permutation importance and minimal depth were consistent with the Shapley-based assignments, notably identifying <italic>DUX4</italic> expression as an important contributor to patient survival outcomes (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). We investigated time-dependent changes in variable importance by estimating Shapley values associated with predicting survival probability at distinct timepoints along the observation window. Interestingly, we observed the strong dependence on ECOG PS for predicting survival at early timepoints under this paradigm. The importance of <italic>DUX4</italic> expression for survival prediction is most prominent at later times (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Altogether, we found that diverse variable importance measures converge on identifying <italic>DUX4</italic> as a major contributor to patient survival prediction.</p><p>We sought to quantify the effect of <italic>DUX4</italic> expression on survival predictions after controlling for the effects of the other covariates. With Shapley dependence plots, which allows visualization of the marginal effects of a variable on the predicted outcome, we measured the expected negative correlation between TMB and mortality (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>; <xref ref-type="bibr" rid="bib70">Lundberg et al., 2020</xref>). We performed a similar dependence analysis on <italic>DUX4</italic> expression and observed a clear separation of positive and negative Shapley values based on <italic>DUX4</italic>-positive and -negative status, respectively. These results signify an increase in predicted risk of death associated with <italic>DUX4</italic> expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G</xref>). Shapley values are scaled, variable attributions which add up to the difference between the prediction for an individual and the average prediction across the entire cohort and thus require transformation to get absolute measures of risk. To quantify the effects of TMB and <italic>DUX4</italic> expression in the appropriate risk units (mortality, expected number of deaths), we utilized partial dependence as an alternative way to represent mortality predictions as a function of these variables, marginalized over the other predictors in the data (<xref ref-type="bibr" rid="bib26">Friedman, 2001</xref>). Specifically, the average model predictions across the individuals in the cohort are calculated over the unique predictor values. The marginal effects of TMB and <italic>DUX4</italic> expression measured via partial and Shapley dependence analyses show strong concordance. Comparison of the patients with the lowest vs. highest TMB revealed an approximately 67% difference in mortality. On the other hand, we measured an approximately 53% increase in mortality associated with <italic>DUX4</italic> positivity (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1H,I</xref>). We then extended the partial dependence analyses to survival probability predictions over time. In this paradigm, we similarly observed that higher TMB was correlated with increased survival probability, more pronounced at later times (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). <italic>DUX4</italic> expression was correlated with poorer survival outcomes, with a 1- and 1.5-year survival difference of 20.7% and 19.2% between patients with <italic>DUX4</italic>+ and <italic>DUX4</italic>− tumors, respectively. Strikingly, our analyses measure a difference of at least 12.5 months in median survival between the <italic>DUX4</italic>+ and <italic>DUX4</italic>− strata (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Overall, our analyses demonstrate a significant and robust decrease in survival attributable to <italic>DUX4</italic> expression in advanced cancers.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p><italic>DUX4</italic> expression is a common feature of metastasis and may be an important driver of immune evasion. While the mechanism governing <italic>DUX4</italic> de-repression in cancer remains to be elucidated, we show that <italic>DUX4</italic> expression in the metastatic context is associated with reduced anti-tumor immunity, mirroring previous observations in primary cancers and cancer cell line models (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>), and is correlated with decreased patient survival under ICI treatment.</p><p>The prognostic value of IFN-γ activity (<xref ref-type="bibr" rid="bib5">Ayers et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Grasso et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Newell et al., 2022</xref>) and its non-redundancy relative to TMB in terms of influencing ICI response is widely appreciated (<xref ref-type="bibr" rid="bib16">Cristescu et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Newell et al., 2022</xref>; <xref ref-type="bibr" rid="bib95">Rozeman et al., 2021</xref>). For example, patients with advanced melanoma that is nonresponsive to anti-CTLA-4 or anti-PD-1/PD-L1 therapy have higher frequencies of genetic alterations associated with IFN-γ signaling defects compared to responsive patients (<xref ref-type="bibr" rid="bib27">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Nguyen et al., 2021</xref>; <xref ref-type="bibr" rid="bib111">Sucker et al., 2017</xref>). DUX4 has been implicated in modifying IFN-γ activity through direct binding and inhibition of STAT1 via its C-terminal domain (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Spens et al., 2023</xref>). Our sequence analyses show that <italic>DUX4</italic> transcripts in the metastatic context contain the full-length coding region, suggestive of an intact capability as a STAT1 suppressor. <italic>DUX4</italic>’s ubiquitous expression across metastatic cancers and our controlled survival analyses emphasize <italic>DUX4</italic> as an underappreciated contributor to ICI resistance.</p><p>Our RSF model allowed us to interrogate changes in variable importance over time. For instance, the contribution of <italic>DUX4</italic> expression to survival prediction is most prominent at later timepoints, suggesting principal effects on long-term survival. Intriguingly, these analyses revealed the outsize influence of ECOG PS, a measure of patient functional status, on survival at early timepoints relative to other patient covariates. ECOG PS negatively impacts patient survival during ICI therapy, inferred from our multivariate Cox PH analysis and from findings of the IMvigor210 clinical trial: patients with ECOG PS = 2 (<italic>n</italic> = 24) had a median overall survival of 8.1 months, lower than the subgroup with ECOG PS &lt;2 (<italic>n</italic> = 35) whose median survival was not reached during the observation period (<xref ref-type="bibr" rid="bib6">Balar et al., 2017</xref>). Other studies have similarly reported poorer outcomes associated with ICI treatment in patients with high ECOG PS (<xref ref-type="bibr" rid="bib12">Chalker et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Krishnan et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Cristescu et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Sehgal et al., 2021</xref>). Altogether, these results possibly indicate the existence of co-occurring conditions in patients with higher degrees of disability, predisposing them to adverse effects associated with ICI treatment— comorbidities whose effects presumably manifest shortly after therapy commencement. Our data underscore the utility of time-dependent approaches in identifying covariate-linked survival effects which may not be apparent in a summary computed over the entire time period.</p><p>Our results may have broad implications for ICI treatment. First, <italic>DUX4</italic> expression may promote patient resistance in a wide array of ICI modalities. Our previous work showed that <italic>DUX4</italic> expression is associated with resistance to anti-CTLA-4 and anti-PD-1 therapies (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>). In our current study, we comprehensively demonstrate that <italic>DUX4</italic> modulates patient response to PD-L1 blockade. We also report that <italic>DUX4</italic> expression in metastasis is correlated with downregulation of <italic>TIGIT</italic> (<xref ref-type="bibr" rid="bib129">Zhang et al., 2018</xref>) and other immune checkpoints whose interception are currently under clinical investigation: <italic>HAVCR2/TIM3</italic> (NCT02608268; <xref ref-type="bibr" rid="bib22">Dixon et al., 2021</xref>) and <italic>LAG3</italic> (NCT02658981; <xref ref-type="bibr" rid="bib2">Amaria et al., 2022</xref>; <xref ref-type="bibr" rid="bib114">Tawbi et al., 2022</xref>). Second, the pervasive expression of <italic>DUX4</italic> in all the metastatic cohorts we examined exhibits its potential as a pan-cancer biomarker. We show that binary categorization of patients according to <italic>DUX4</italic> expression status was sufficient to stratify patients according to ICI response. Screening for <italic>DUX4</italic> tumor expression, with binarized results such as through IHC using anti-DUX4 antibodies, could have clinical utility.</p><p>Our data motivate the investigation into <italic>DUX4</italic>’s potential to prognosticate response to ICI. However, our current study is limited by the availability of sufficiently sized ICI-treated cohorts with associated patient data on relevant characteristics such as demographics and risk factors. Additional randomized trial data from diverse metastatic cancer cohorts, with adequate genomic and clinical data, is imperative. As these become available in the future, extending the analyses we have outlined in this study will be important to appraise <italic>DUX4</italic>’s definitive clinical relevance, contextualized among response-modifying clinical variables, in the use of immunotherapy in the treatment of metastatic cancer.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">UCSC knownGene</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib75">Meyer et al., 2013</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23155063/">23155063</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Ensembl 71</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Flicek et al., 2013</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23203987/">23203987</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MISO v2.0</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib54">Katz et al., 2010</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21057496/">21057496</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RSEM v1.2.4</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Li and Dewey, 2011</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/21816040/">21816040</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Bowtie v1.0.0</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Langmead et al., 2009</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19261174/">19261174</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">TopHat v.2.0.8b</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib118">Trapnell et al., 2009</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/19289445/">19289445</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Trimmed mean of <italic>M</italic> values (TMM) method</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib91">Robinson and Oshlack, 2010</xref>; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/20196867/">20196867</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">clusterProfiler</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib123">Wu et al., 2021</xref>; <xref ref-type="bibr" rid="bib127">Yu et al., 2012</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34557778/">34557778</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22455463/">22455463</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">samtools</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib63">Li et al., 2009</xref>;<break/> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22517427/">19505943</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">kallisto v.0.46.1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">Bray et al., 2016</xref>; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/27043002/">27043002</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Integrative Genomics Viewer</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib117">Thorvaldsdóttir et al., 2013</xref>; <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22517427/">22517427</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">survival</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib115">Therneau and Grambsch, 2000</xref>;<break/> <xref ref-type="bibr" rid="bib116">Therneau, 2022</xref>; <ext-link ext-link-type="uri" xlink:href="https://github.com/therneau/survival">https://github.com/therneau/survival</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">stats</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib89">R Development Core Team, 2022</xref>;<break/> <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">caret</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Kuhn, 2022</xref>;<break/> <ext-link ext-link-type="uri" xlink:href="https://github.com/topepo/caret/">https://github.com/topepo/caret/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ggplot2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib120">Wickham, 2016</xref>; <break/><ext-link ext-link-type="uri" xlink:href="https://github.com/tidyverse/ggplot2">https://github.com/tidyverse/ggplot2</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">dplyr</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib121">Wickham et al., 2022</xref>;<break/> <ext-link ext-link-type="uri" xlink:href="https://github.com/tidyverse/dplyr">https://github.com/tidyverse/dplyr</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">survminer</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib53">Kassambara et al., 2021</xref>; <ext-link ext-link-type="uri" xlink:href="https://rpkgs.datanovia.com/survminer/index.html">https://rpkgs.datanovia.com/survminer/index.html</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">randomForestSRC</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>; <ext-link ext-link-type="uri" xlink:href="https://www.randomforestsrc.org/articles/survival.html">https://www.randomforestsrc.org/articles/survival.html</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">fastshap</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Greenwell, 2021</xref>; <ext-link ext-link-type="uri" xlink:href="https://github.com/bgreenwell/fastshap">https://github.com/bgreenwell/fastshap</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">pammtools</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib7">Bender and Scheipl, 2018</xref>; <ext-link ext-link-type="uri" xlink:href="https://adibender.github.io/pammtools/">https://adibender.github.io/pammtools/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">plotly</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib102">Sievert, 2020</xref>; <ext-link ext-link-type="uri" xlink:href="https://plotly.com/r/">https://plotly.com/r/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">timeROC</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Blanche et al., 2013</xref>;<break/> <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=timeROC">https://CRAN.R-project.org/package=timeROC</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">pec</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib77">Mogensen et al., 2012</xref>;<break/> <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=pec">https://CRAN.R-project.org/package=pec</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Datasets analyzed in this study</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Dataset name</th><th align="left" valign="bottom">Accession number(s)</th><th align="left" valign="bottom">PMID(s)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">2013/TCGA.ACC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.BLCA</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.BRCA</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.CESC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.CHOL</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.COAD</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.DLBC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.ESCA</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.GBM</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.HNSC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.KICH</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.KIRC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.KIRP</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.LAML</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.LGG</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.LIHC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.LUAD</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.LUSC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.MESO</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.OV</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.PAAD</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.PCPG</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.PRAD</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.READ</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.SARC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.SKCM</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.STAD</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.TGCT</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.THCA</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.THYM</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.UCEC</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.UCS</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">2013/TCGA.UVM</td><td align="left" valign="bottom">NCI Genomic Data Commons</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">2014/su2c.prostate_cancer</td><td align="left" valign="bottom">phs000915.v1.p1 (dbGaP)</td><td align="char" char="." valign="bottom">26000489</td></tr><tr><td align="left" valign="bottom">2016/chen-chen.acute_lymphoblastic_leukemia</td><td align="left" valign="bottom">Chinese Genotype-phenotype Archive</td><td align="char" char="." valign="bottom">27428428</td></tr><tr><td align="left" valign="bottom">2016/fioretos.acute_lymphoblastic_leukemia</td><td align="left" valign="bottom">EGAD00001002112 (EGA)</td><td align="char" char="." valign="bottom">27265895</td></tr><tr><td align="left" valign="bottom">2016/mano.acute_lymphoblastic_leukemia</td><td align="left" valign="bottom">JGAS00000000047 (JGA)</td><td align="char" char="." valign="bottom">27019113</td></tr><tr><td align="left" valign="bottom">2015/garraway-schadendorf.melanoma_checkpoint_blockade</td><td align="left" valign="bottom">phs000452.v2.p1 (dbGaP)</td><td align="char" char="." valign="bottom">26359337</td></tr><tr><td align="left" valign="bottom">2016/hammerbacher.melanoma_checkpoint_blockade</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">27956380</td></tr><tr><td align="left" valign="bottom">2016/lo.melanoma_checkpoint_blockade</td><td align="left" valign="bottom">GSE78220 (GEO)</td><td align="char" char="." valign="bottom">26997480</td></tr><tr><td align="left" valign="bottom">2017/chinnaiyan.metastatic_cancer</td><td align="left" valign="bottom">phs000673.v3.p1 (dbGaP)</td><td align="char" char="." valign="bottom">28783718</td></tr><tr><td align="left" valign="bottom">2017/yang-yeoh.acute_lymphoblastic_leukemia</td><td align="left" valign="bottom">EGAD00001002151 (EGA)</td><td align="char" char="." valign="bottom">27903646</td></tr><tr><td align="left" valign="bottom">2018/perou.metastatic_breast_cancer</td><td align="left" valign="bottom">phs000676.v2.p2 (dbGaP)</td><td align="char" char="." valign="bottom">29480819</td></tr><tr><td align="left" valign="bottom">2018/powles.urothelial_cancer_checkpoint_blockade</td><td align="left" valign="bottom">EGAD00001003977 (EGA)</td><td align="char" char="." valign="bottom">29443960</td></tr><tr><td align="left" valign="bottom">2018/van_allen-choueiri.clear_cell_checkpoint_blockade</td><td align="left" valign="bottom">phs001493.v1.p1 (dbGaP)</td><td align="char" char="." valign="bottom">29301960</td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Genome annotations, gene expression, and GO enrichment analyses</title><p>A genome annotation was created through merging of the UCSC knownGene (<xref ref-type="bibr" rid="bib75">Meyer et al., 2013</xref>), Ensembl 71 (<xref ref-type="bibr" rid="bib25">Flicek et al., 2013</xref>), and MISO v2.0 (<xref ref-type="bibr" rid="bib54">Katz et al., 2010</xref>) annotations for the hg19/GRCh37 assembly. Furthermore, this annotation was expanded by generating all possible combinations of annotated 5′ and 3′ splice sites within each gene. RNA-seq reads were mapped to the transcriptome using RSEM v1.2.4 (<xref ref-type="bibr" rid="bib64">Li and Dewey, 2011</xref>) calling Bowtie v1.0.0 (<xref ref-type="bibr" rid="bib59">Langmead et al., 2009</xref>), with the option ‘-v 2’. TopHat v.2.0.8b (<xref ref-type="bibr" rid="bib118">Trapnell et al., 2009</xref>) was used to map the unaligned reads to the genome and to the database of splice junctions obtained from the annotation merging described previously. Gene expression estimates (TPM, transcripts per million) obtained were normalized using the trimmed mean of <italic>M</italic> values (TMM) method (<xref ref-type="bibr" rid="bib91">Robinson and Oshlack, 2010</xref>). Endogenous expression of <italic>DUX4</italic> during early embryogenesis range from approximately 2 to 10 TPM (<xref ref-type="bibr" rid="bib13">Chew et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Hendrickson et al., 2017</xref>). We have therefore defined DUX4-positive samples as those with expression levels &gt;1 TPM. In the differential gene expression analyses for the DUX4-positive vs. -negative comparison, gene expression values per sample group were compared using a two-sided Mann–Whitney <italic>U</italic> test. Differentially expressed genes illustrated in <xref ref-type="fig" rid="fig2">Figure 2B</xref> were identified as those with an absolute log<sub>2</sub>(fold-change) ≥ log<sub>2</sub>(1.25) and a p-value &lt;0.05. GO enrichment analyses, using the clusterProfiler package (<xref ref-type="bibr" rid="bib123">Wu et al., 2021</xref>; <xref ref-type="bibr" rid="bib127">Yu et al., 2012</xref>), were performed on <italic>DUX4</italic>-upregulated or -downregulated genes [absolute log<sub>2</sub>(fold-change) ≥ log<sub>2</sub>(1.5) and a p-value &lt;0.05] compared against the set of coding genes. Significant GO terms were defined as ‘Biological Process’ terms with a Benjamini–Hochberg FDR-adjusted p-value &lt;0.05. The top 25 significant GO terms were illustrated (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). To investigate <italic>DUX4</italic> RNA-seq coverage patterns, a fasta file containing the <italic>DUX4</italic> cDNA sequence was assembled, indexed using samtools (<xref ref-type="bibr" rid="bib63">Li et al., 2009</xref>), and used as a reference for read pseudoalignment by kallisto v.0.46.1 (<xref ref-type="bibr" rid="bib9">Bray et al., 2016</xref>). The following kallisto parameters were used: kmer size of 31, estimated fragment length of 200, and estimated fragment length standard deviation of 80. Usage of the single-end option (‘--single’) and bias correction (‘--bias’) were also specified. <italic>DUX4</italic> read coverage was visualized using the Integrative Genomics Viewer (IGV, <xref ref-type="bibr" rid="bib117">Thorvaldsdóttir et al., 2013</xref>).</p></sec><sec id="s4-3"><title>Gene signature analyses</title><p>For a given gene set, <italic>z</italic>-score normalization of the expression values per gene was performed across the patient cohort. The signature score was defined as the mean of the normalized values across the genes of the set.</p></sec><sec id="s4-4"><title>Survival analyses, goodness-of-fit measures, and risk modeling</title><p>KM estimation, p-value estimates from the log-rank test, and Cox PH regression in the univariate and multivariate contexts were performed using the survival package (<xref ref-type="bibr" rid="bib116">Therneau, 2022</xref>; <xref ref-type="bibr" rid="bib115">Therneau and Grambsch, 2000</xref>). Goodness-of-fit evaluations of the Cox PH models were done by measuring the Akaike information criterion (AIC) and Bayesian information criterion (BIC). AIC and BIC metrics balance model complexity with maximized likelihood, penalizing feature number increases without a concomitant improvement in performance. The likelihood ratio test was also used to compare goodness of fit of full (all variables) vs. reduced (subset of variables) Cox PH models. Specifically, the null hypothesis that the simple model provides as good as a fit as the more complex model was evaluated. The AIC, BIC, and likelihood ratio test p-values were computed using R’s stats package (<xref ref-type="bibr" rid="bib89">R Development Core Team, 2022</xref>). For the Cox PH risk modeling, the patients were randomly assigned into training (70%) and test (30%) datasets. The createDataPartition() function from the caret package (<xref ref-type="bibr" rid="bib58">Kuhn, 2022</xref>) was used to preserve the <italic>DUX4</italic> status class distribution after splitting. Full and reduced Cox PH models were created using the training data and the risk scores for each respective model were calculated using caret’s predict.coxph() function. For a given patient, the calculated risk score is equal to the HR relative to a ‘reference patient’ (an individual whose covariate values are set to the respective means, from the training set). Specifically, the risk score is the quotient of the patient’s and the reference’s exponentiated linear predictors (the sum of the covariates in the model, weighted by the model’s regression coefficients). A ‘reference risk score’ for each model was defined as the median risk score in the training data. Patients were assigned into low- or high-risk groups if their risk scores were lower or higher than the reference, respectively. The trained models were used to calculate risk scores and assign risk labels (based on the training set risk score reference) in the test set. The survival difference between low- and high-risk patients was empirically assessed via KM estimation and the log-rank test. Visualizations were created using the ggplot2 (<xref ref-type="bibr" rid="bib120">Wickham, 2016</xref>), dplyr (<xref ref-type="bibr" rid="bib121">Wickham et al., 2022</xref>), and survminer (<xref ref-type="bibr" rid="bib53">Kassambara et al., 2021</xref>) packages.</p></sec><sec id="s4-5"><title>Random Survival Forest, feature importance, and partial dependence</title><p>We implemented an RSF model, an ensemble of multiple base learners (survival trees), using the randomForestSRC package (<xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>). The RSF algorithm is an extension of the Random Forest Algorithm (<xref ref-type="bibr" rid="bib10">Breiman, 2001</xref>) for usage with right-censored data. Here, B bootstrap datasets are created from the original data, used to grow B concomitant survival trees (usually constrained by membership size in the terminal nodes) constructed using a randomly selected subset of the variables. Terminal node statistics are obtained for each tree: the survival function (via the KM estimator), the cumulative hazard function (CHF, via the Nelson–Aalen estimator), and mortality (expected number of deaths; sum of the CHF over time). The RSF prediction is the average across the forest. Of note, each bootstrap dataset excludes 36.8% of the original data on average, the OOB samples. Thus, predictions for a particular sample can be made using the subset of the trees for which it was excluded from training (OOB predictions). Similarly, the associated OOB error for the RSF model can calculated, representing an unbiased estimate of the test error. We randomly assigned patients into training (70%) and test (30%) datasets. Since the <italic>DUX4</italic>-positive status was a minority class, we utilized the createDataPartition() function from the caret package (<xref ref-type="bibr" rid="bib58">Kuhn, 2022</xref>) to preserve the class distribution within the splits. To determine optimal hyperparameters, we evaluated 5616 RSF models representing different combinations of ntree (number of trees), nodesize (minimum terminal node size), mtry (number of randomly selected splitting variables), na.action (handling of missing data), splitrule (splitting rule), and samptype (type of bootstrap). We selected the model with hyperparameters which minimized both the OOB training and the test errors (defined as 1 − concordance index), namely: ntree = 1500, nodesize = 15, mtry = 3, na.action = &quot;na.impute&quot;, splitrule = &quot;bs.gradient&quot;, and samptype = &quot;swr&quot;. We specified the use of an nsplit (number of random splits) value of 0 to indicate evaluation of all possible split points and usage of the optimum. For test set predictions, patients with missing data were omitted (na.action = &quot;na.omit&quot;).</p><p>Feature importance in the final RSF model was evaluated using three metrics. First, permutation importance was measured using randomForestSRC’s subsample() function. RSF permutation importance utilizes OOB values: a variable’s OOB data is permuted and the change in the new vs. original OOB prediction error is quantified. The RSF permutation importance values were standardized by dividing by the variance and multiplying by 100, and the variance and confidence regions were obtained via the delete-<italic>d</italic> jackknife estimator (<xref ref-type="bibr" rid="bib46">Ishwaran and Lu, 2019</xref>). Second, the tree-based feature importance metric minimal depth was calculated using randomForestSRC’s var.select() function. The minimal depth threshold (mean minimal depth) is the tree-averaged threshold (conservative = &quot;medium&quot;). Last, Shapley values were estimated using the fastshap package (<xref ref-type="bibr" rid="bib34">Greenwell, 2021</xref>), using 1000 Monte Carlo repetitions. For each prediction, the sum of the estimated Shapley values was corrected (adjust = TRUE) to satisfy the efficiency (or local accuracy) property: for an individual <italic>i</italic>, the sum of <italic>i</italic>’s feature contributions equal the difference between the prediction for <italic>i</italic> and the average prediction across the entire cohort. For the overall measure of importance, the Shapley values were estimated from the mortality predictions from the RSF model (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). Mortality is defined as the number of expected deaths over the observation window. That is, if all patients in the cohort shared the same covariate values as patient <italic>i</italic> who has mortality <italic>m<sub>i</sub></italic>, then an average of <italic>m</italic> deaths is expected (<xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>). For the time-dependent implementation, we estimated Shapley values associated with the per timepoint RSF survival probability predictions along the observation window (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><p>The relationships of <italic>DUX4</italic> expression and TMB to mortality or survival probability (marginal contributions) were assessed via Shapley dependence plots and partial dependence plots. Partial dependence values were obtained using randomForestSRC’s partial() function and OOB predictions for mortality and survival probability were used as input. Visualizations were created in the R programming environment using the dplyr (<xref ref-type="bibr" rid="bib121">Wickham et al., 2022</xref>), ggplot2 (<xref ref-type="bibr" rid="bib120">Wickham, 2016</xref>), pammtools (<xref ref-type="bibr" rid="bib7">Bender and Scheipl, 2018</xref>), and plotly (<xref ref-type="bibr" rid="bib102">Sievert, 2020</xref>) packages.</p></sec><sec id="s4-6"><title>Measuring survival model predictive accuracy</title><p>The time-dependent ROC curve analyses were done to evaluate the RSF model’s accuracy in differentiating patients who die before a particular time <italic>t</italic>, from those who survive past <italic>t</italic> (<xref ref-type="bibr" rid="bib36">Heagerty and Zheng, 2005</xref>). Specifically, for each timepoint, the cumulative/dynamic area under the ROC curve (AUC<sup>C/D</sup>) was calculated by computing the sensitivity (true positive rate) and specificity (1 − false positive rate) associated with using RSF-predicted mortality as the prognostic marker. The time-dependent AUC<sup>C/D</sup> and 95% confidence interval per timepoint were estimated using the timeROC package, which adds the inverse-probability-of-censoring weights (IPCW) to the sensitivity calculation to correct for selection bias due to right-censoring (<xref ref-type="bibr" rid="bib8">Blanche et al., 2013</xref>). The OOB (training) or the test mortality predictions were used as input. The time-dependent Brier score and the Continuous Ranked Probability Score (CRPS, integrated Brier score divided by time) for the Cox PH models were computed using the pec package (<xref ref-type="bibr" rid="bib77">Mogensen et al., 2012</xref>). The time-dependent Brier score and the CRPS for the RSF model was calculated using the randomForestSRC package (<xref ref-type="bibr" rid="bib42">Ishwaran et al., 2008</xref>). The KM estimator for the censoring times was used to estimate the IPCW (cens.model = &quot;marginal&quot;). Harrell’s concordance index for the Cox PH and RSF models was calculated using the survival (<xref ref-type="bibr" rid="bib116">Therneau, 2022</xref>; <xref ref-type="bibr" rid="bib115">Therneau and Grambsch, 2000</xref>) and randomForestSRC packages, respectively. Visualizations were created in the R programming environment using the dplyr and ggplot2 (<xref ref-type="bibr" rid="bib120">Wickham, 2016</xref>) packages.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>This author is an inventor on a patent application submitted by Fred Hutchinson Cancer Center that covers DUX4 expression in cancers and response to immunotherapy (PCT/US2019/043396). This author is a founder and scientific advisor of Codify Therapeutics and Synthesize Bio and holds equity in both companies. This author has received research funding from Codify Therapeutics unrelated to the current work</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Cox Proportional Hazards regression for overall survival.</title><p>Hazard ratios, 95% confidence intervals, and p-values for patient covariates in the IMvigor210 urothelial carcinoma cohort, estimated under either the univariate or multivariate Cox Proportional Hazards model. Adjusted p-values were estimated via the Benjamini–Hochberg correction.</p></caption><media xlink:href="elife-89017-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Cox Proportional Hazards regression for overall survival (TGFB1 expression included).</title><p>As in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, but <italic>TGFB1</italic> expression is included in the models.</p></caption><media xlink:href="elife-89017-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Likelihood ratio test.</title><p>Estimated p-values from the likelihood ratio test, comparing the goodness of fit of the specified competing models.</p></caption><media xlink:href="elife-89017-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-89017-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Accession information for RNA sequencing and patient data analyzed in this study are detailed in the appendix. The DUX4 transcript sequence from the hg19 assembly was obtained from the UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/">https://genome.ucsc.edu/</ext-link>). Any additional information required to reanalyze the data reported in this paper is available from the corresponding author upon request.</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Nickles</surname><given-names>D</given-names></name><name><surname>Castiglioni</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kadel III</surname><given-names>EE</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Astarita</surname><given-names>JL</given-names></name><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Banchereau</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Chalouni</surname><given-names>C</given-names></name><name><surname>Ziai</surname><given-names>J</given-names></name><name><surname>Şenbabaoğlu</surname><given-names>Y</given-names></name><name><surname>Santoro</surname><given-names>S</given-names></name><name><surname>Sheinson</surname><given-names>D</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Giltnane</surname><given-names>JM</given-names></name><name><surname>Pierce</surname><given-names>AA</given-names></name><name><surname>Mesh</surname><given-names>K</given-names></name><name><surname>Lianoglou</surname><given-names>S</given-names></name><name><surname>Riegler</surname><given-names>J</given-names></name><name><surname>Carano</surname><given-names>RAD</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Höglund</surname><given-names>M</given-names></name><name><surname>Somarriba</surname><given-names>L</given-names></name><name><surname>Halligan</surname><given-names>DL</given-names></name><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Derleth</surname><given-names>C</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Tumor gene expression profiles for the study 'TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells'</data-title><source>European Genome-Phenome Archive</source><pub-id pub-id-type="accession" xlink:href="https://ega-archive.org/datasets/EGAD00001003977">EGAD00001003977</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>RKB was supported in part by the NIH/NCI (R01 CA251138), NIH/NHLBI (R01 HL128239, R01 HL151651), and the Blood Cancer Discoveries Grant program through the Leukemia &amp; Lymphoma Society, Mark Foundation for Cancer Research, and Paul G Allen Frontiers Group (8023-20). RKB is a Scholar of The Leukemia &amp; Lymphoma Society (1344-18) and holds the McIlwain Family Endowed Chair in Data Science. The results shown here are in part based upon data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alspach</surname><given-names>E</given-names></name><name><surname>Lussier</surname><given-names>DM</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>11</volume><elocation-id>a028480</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028480</pub-id><pub-id pub-id-type="pmid">29661791</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaria</surname><given-names>RN</given-names></name><name><surname>Postow</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>EM</given-names></name><name><surname>Tetzlaff</surname><given-names>MT</given-names></name><name><surname>Ross</surname><given-names>MI</given-names></name><name><surname>Torres-Cabala</surname><given-names>C</given-names></name><name><surname>Glitza</surname><given-names>IC</given-names></name><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Milton</surname><given-names>DR</given-names></name><name><surname>Busam</surname><given-names>K</given-names></name><name><surname>Simpson</surname><given-names>L</given-names></name><name><surname>McQuade</surname><given-names>JL</given-names></name><name><surname>Wong</surname><given-names>MK</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Goepfert</surname><given-names>RP</given-names></name><name><surname>Keung</surname><given-names>EZ</given-names></name><name><surname>Fisher</surname><given-names>SB</given-names></name><name><surname>Betof-Warner</surname><given-names>A</given-names></name><name><surname>Shoushtari</surname><given-names>AN</given-names></name><name><surname>Callahan</surname><given-names>M</given-names></name><name><surname>Coit</surname><given-names>D</given-names></name><name><surname>Bartlett</surname><given-names>EK</given-names></name><name><surname>Bello</surname><given-names>D</given-names></name><name><surname>Momtaz</surname><given-names>P</given-names></name><name><surname>Nicholas</surname><given-names>C</given-names></name><name><surname>Gu</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Korivi</surname><given-names>BR</given-names></name><name><surname>Patnana</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Diab</surname><given-names>A</given-names></name><name><surname>Lucci</surname><given-names>A</given-names></name><name><surname>Prieto</surname><given-names>VG</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Ariyan</surname><given-names>C</given-names></name><name><surname>Tawbi</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Neoadjuvant relatlimab and nivolumab in resectable melanoma</article-title><source>Nature</source><volume>611</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05368-8</pub-id><pub-id pub-id-type="pmid">36289334</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Owosho</surname><given-names>AA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Deniz</surname><given-names>K</given-names></name><name><surname>Huryn</surname><given-names>JM</given-names></name><name><surname>Kao</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Tap</surname><given-names>W</given-names></name><name><surname>Schaefer</surname><given-names>IM</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Sarcomas with cic-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases</article-title><source>The American Journal of Surgical Pathology</source><volume>41</volume><fpage>941</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000846</pub-id><pub-id pub-id-type="pmid">28346326</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Ferrucci</surname><given-names>PF</given-names></name><name><surname>Fisher</surname><given-names>R</given-names></name><name><surname>Del Vecchio</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>V</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>Queirolo</surname><given-names>P</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Di Giacomo</surname><given-names>AM</given-names></name><name><surname>Svane</surname><given-names>IM</given-names></name><name><surname>Lotem</surname><given-names>M</given-names></name><name><surname>Bar-Sela</surname><given-names>G</given-names></name><name><surname>Couture</surname><given-names>F</given-names></name><name><surname>Mookerjee</surname><given-names>B</given-names></name><name><surname>Ghori</surname><given-names>R</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Moreno</surname><given-names>BH</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma</article-title><source>Nature Medicine</source><volume>25</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0448-9</pub-id><pub-id pub-id-type="pmid">31171878</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Lunceford</surname><given-names>J</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Loboda</surname><given-names>A</given-names></name><name><surname>Kaufman</surname><given-names>DR</given-names></name><name><surname>Albright</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>JD</given-names></name><name><surname>Kang</surname><given-names>SP</given-names></name><name><surname>Shankaran</surname><given-names>V</given-names></name><name><surname>Piha-Paul</surname><given-names>SA</given-names></name><name><surname>Yearley</surname><given-names>J</given-names></name><name><surname>Seiwert</surname><given-names>TY</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>McClanahan</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</article-title><source>The Journal of Clinical Investigation</source><volume>127</volume><fpage>2930</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1172/JCI91190</pub-id><pub-id pub-id-type="pmid">28650338</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balar</surname><given-names>AV</given-names></name><name><surname>Galsky</surname><given-names>MD</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Necchi</surname><given-names>A</given-names></name><name><surname>Hoffman-Censits</surname><given-names>J</given-names></name><name><surname>Perez-Gracia</surname><given-names>JL</given-names></name><name><surname>Dawson</surname><given-names>NA</given-names></name><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Dreicer</surname><given-names>R</given-names></name><name><surname>Srinivas</surname><given-names>S</given-names></name><name><surname>Retz</surname><given-names>MM</given-names></name><name><surname>Joseph</surname><given-names>RW</given-names></name><name><surname>Drakaki</surname><given-names>A</given-names></name><name><surname>Vaishampayan</surname><given-names>UN</given-names></name><name><surname>Sridhar</surname><given-names>SS</given-names></name><name><surname>Quinn</surname><given-names>DI</given-names></name><name><surname>Durán</surname><given-names>I</given-names></name><name><surname>Shaffer</surname><given-names>DR</given-names></name><name><surname>Eigl</surname><given-names>BJ</given-names></name><name><surname>Grivas</surname><given-names>PD</given-names></name><name><surname>Yu</surname><given-names>EY</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Kadel</surname><given-names>EE</given-names></name><name><surname>Boyd</surname><given-names>Z</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Thåström</surname><given-names>A</given-names></name><name><surname>Abidoye</surname><given-names>OO</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Bajorin</surname><given-names>DF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial</article-title><source>The Lancet</source><volume>389</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32455-2</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Bender</surname><given-names>A</given-names></name><name><surname>Scheipl</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pammtools: Piece-Wise Exponential Additive Mixed Modeling Tools</article-title><source>arXiv</source><pub-id pub-id-type="doi">10.48550/arXiv.1806.01042</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanche</surname><given-names>P</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Jacqmin-Gadda</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks</article-title><source>Statistics in Medicine</source><volume>32</volume><fpage>5381</fpage><lpage>5397</lpage><pub-id pub-id-type="doi">10.1002/sim.5958</pub-id><pub-id pub-id-type="pmid">24027076</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>NL</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id><pub-id pub-id-type="pmid">27043002</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breiman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Random forests</article-title><source>Machine Learning</source><volume>45</volume><fpage>5</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1023/A:1010933404324</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bylander</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Estimating generalization error on two-class datasets using out-of-bag estimates</article-title><source>Machine Learning</source><volume>48</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1023/A:1013964023376</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalker</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>H</given-names></name><name><surname>Cranfield</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Efficacy of low-dose and/or adjuvant methadone in palliative medicine</article-title><source>BMJ Supportive &amp; Palliative Care</source><volume>12</volume><fpage>e730</fpage><lpage>e735</lpage><pub-id pub-id-type="doi">10.1136/bmjspcare-2018-001695</pub-id><pub-id pub-id-type="pmid">30952645</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>GL</given-names></name><name><surname>Campbell</surname><given-names>AE</given-names></name><name><surname>De Neef</surname><given-names>E</given-names></name><name><surname>Sutliff</surname><given-names>NA</given-names></name><name><surname>Shadle</surname><given-names>SC</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>DUX4 suppresses mhc class i to promote cancer immune evasion and resistance to checkpoint blockade</article-title><source>Developmental Cell</source><volume>50</volume><fpage>658</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.06.011</pub-id><pub-id pub-id-type="pmid">31327741</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>EYK</given-names></name><name><surname>Thomas</surname><given-names>DG</given-names></name><name><surname>McHugh</surname><given-names>JB</given-names></name><name><surname>Patel</surname><given-names>RM</given-names></name><name><surname>Roulston</surname><given-names>D</given-names></name><name><surname>Schuetze</surname><given-names>SM</given-names></name><name><surname>Chugh</surname><given-names>R</given-names></name><name><surname>Biermann</surname><given-names>JS</given-names></name><name><surname>Lucas</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology</article-title><source>The American Journal of Surgical Pathology</source><volume>37</volume><fpage>1379</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e318297a57d</pub-id><pub-id pub-id-type="pmid">23887164</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppola</surname><given-names>D</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><name><surname>Khalil</surname><given-names>F</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Yeatman</surname><given-names>T</given-names></name><name><surname>Loboda</surname><given-names>A</given-names></name><name><surname>Mulé</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling</article-title><source>The American Journal of Pathology</source><volume>179</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.03.007</pub-id><pub-id pub-id-type="pmid">21703392</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristescu</surname><given-names>R</given-names></name><name><surname>Mogg</surname><given-names>R</given-names></name><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Albright</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Yearley</surname><given-names>J</given-names></name><name><surname>Sher</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lunceford</surname><given-names>JK</given-names></name><name><surname>Joe</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Webber</surname><given-names>AL</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Plimack</surname><given-names>ER</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Seiwert</surname><given-names>TY</given-names></name><name><surname>Kaufman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy</article-title><source>Science</source><volume>362</volume><elocation-id>6411</elocation-id><pub-id pub-id-type="doi">10.1126/science.aar3593</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danaher</surname><given-names>P</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Dennis</surname><given-names>L</given-names></name><name><surname>D’Amico</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>A</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name><name><surname>Geller</surname><given-names>MA</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Beechem</surname><given-names>J</given-names></name><name><surname>Fling</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gene expression markers of tumor infiltrating leukocytes</article-title><source>Journal for Immunotherapy of Cancer</source><volume>5</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/s40425-017-0215-8</pub-id><pub-id pub-id-type="pmid">28239471</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Chadwick</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Influence of repressive histone and dna methylation upon d4z4 transcription in non-myogenic cells</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0160022</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160022</pub-id><pub-id pub-id-type="pmid">27467759</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Iaco</surname><given-names>A</given-names></name><name><surname>Planet</surname><given-names>E</given-names></name><name><surname>Coluccio</surname><given-names>A</given-names></name><name><surname>Verp</surname><given-names>S</given-names></name><name><surname>Duc</surname><given-names>J</given-names></name><name><surname>Trono</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DUX-family transcription factors regulate zygotic genome activation in placental mammals</article-title><source>Nature Genetics</source><volume>49</volume><fpage>941</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/ng.3858</pub-id><pub-id pub-id-type="pmid">28459456</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ES</given-names></name><name><surname>Jenkins</surname><given-names>RW</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Dries</surname><given-names>R</given-names></name><name><surname>Yates</surname><given-names>K</given-names></name><name><surname>Chhabra</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Aref</surname><given-names>AR</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Paweletz</surname><given-names>CP</given-names></name><name><surname>Bowden</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>CW</given-names></name><name><surname>Herter-Sprie</surname><given-names>GS</given-names></name><name><surname>Sorrentino</surname><given-names>JA</given-names></name><name><surname>Bisi</surname><given-names>JE</given-names></name><name><surname>Lizotte</surname><given-names>PH</given-names></name><name><surname>Merlino</surname><given-names>AA</given-names></name><name><surname>Quinn</surname><given-names>MM</given-names></name><name><surname>Bufe</surname><given-names>LE</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Cavanaugh</surname><given-names>ME</given-names></name><name><surname>Rode</surname><given-names>AJ</given-names></name><name><surname>Haines</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>PJ</given-names></name><name><surname>Strum</surname><given-names>JC</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><name><surname>Lorch</surname><given-names>JH</given-names></name><name><surname>Parangi</surname><given-names>S</given-names></name><name><surname>Gunda</surname><given-names>V</given-names></name><name><surname>Boland</surname><given-names>GM</given-names></name><name><surname>Bueno</surname><given-names>R</given-names></name><name><surname>Palakurthi</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Ritz</surname><given-names>J</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name><name><surname>Arthanari</surname><given-names>H</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CDK4/6 inhibition augments antitumor immunity by enhancing t-cell activation</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>216</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0915</pub-id><pub-id pub-id-type="pmid">29101163</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>S</given-names></name><name><surname>Floegel</surname><given-names>A</given-names></name><name><surname>Troll</surname><given-names>M</given-names></name><name><surname>Kühn</surname><given-names>T</given-names></name><name><surname>Rathmann</surname><given-names>W</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Sookthai</surname><given-names>D</given-names></name><name><surname>von Bergen</surname><given-names>M</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Adamski</surname><given-names>J</given-names></name><name><surname>Prehn</surname><given-names>C</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Schulze</surname><given-names>MB</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Knüppel</surname><given-names>S</given-names></name><name><surname>Wang-Sattler</surname><given-names>R</given-names></name><name><surname>Drogan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Random survival forest in practice: a method for modelling complex metabolomics data in time to event analysis</article-title><source>International Journal of Epidemiology</source><volume>45</volume><fpage>1406</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1093/ije/dyw145</pub-id><pub-id pub-id-type="pmid">27591264</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>KO</given-names></name><name><surname>Tabaka</surname><given-names>M</given-names></name><name><surname>Schramm</surname><given-names>MA</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TIM-3 restrains anti-tumour immunity by regulating inflammasome activation</article-title><source>Nature</source><volume>595</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03626-9</pub-id><pub-id pub-id-type="pmid">34108686</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doki</surname><given-names>Y</given-names></name><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wyrwicz</surname><given-names>L</given-names></name><name><surname>Motoyama</surname><given-names>S</given-names></name><name><surname>Ogata</surname><given-names>T</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Adenis</surname><given-names>A</given-names></name><name><surname>El Hajbi</surname><given-names>F</given-names></name><name><surname>Di Bartolomeo</surname><given-names>M</given-names></name><name><surname>Braghiroli</surname><given-names>MI</given-names></name><name><surname>Holtved</surname><given-names>E</given-names></name><name><surname>Ostoich</surname><given-names>SA</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Mansoor</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>WC</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Bridgewater</surname><given-names>J</given-names></name><name><surname>Makino</surname><given-names>T</given-names></name><name><surname>Xynos</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Gricar</surname><given-names>J</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma</article-title><source>The New England Journal of Medicine</source><volume>386</volume><fpage>449</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2111380</pub-id><pub-id pub-id-type="pmid">35108470</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>PJR</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>McNamara</surname><given-names>E</given-names></name><name><surname>Hong</surname><given-names>R</given-names></name><name><surname>Moskalenko</surname><given-names>M</given-names></name><name><surname>Gould</surname><given-names>SE</given-names></name><name><surname>Maecker</surname><given-names>H</given-names></name><name><surname>Irving</surname><given-names>BA</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MAP kinase inhibition promotes t cell and anti-tumor activity in combination with pd-l1 checkpoint blockade</article-title><source>Immunity</source><volume>44</volume><fpage>609</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.01.024</pub-id><pub-id pub-id-type="pmid">26944201</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Amode</surname><given-names>MR</given-names></name><name><surname>Barrell</surname><given-names>D</given-names></name><name><surname>Beal</surname><given-names>K</given-names></name><name><surname>Brent</surname><given-names>S</given-names></name><name><surname>Carvalho-Silva</surname><given-names>D</given-names></name><name><surname>Clapham</surname><given-names>P</given-names></name><name><surname>Coates</surname><given-names>G</given-names></name><name><surname>Fairley</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>S</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>García-Girón</surname><given-names>C</given-names></name><name><surname>Gordon</surname><given-names>L</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Juettemann</surname><given-names>T</given-names></name><name><surname>Kähäri</surname><given-names>AK</given-names></name><name><surname>Keenan</surname><given-names>S</given-names></name><name><surname>Komorowska</surname><given-names>M</given-names></name><name><surname>Kulesha</surname><given-names>E</given-names></name><name><surname>Longden</surname><given-names>I</given-names></name><name><surname>Maurel</surname><given-names>T</given-names></name><name><surname>McLaren</surname><given-names>WM</given-names></name><name><surname>Muffato</surname><given-names>M</given-names></name><name><surname>Nag</surname><given-names>R</given-names></name><name><surname>Overduin</surname><given-names>B</given-names></name><name><surname>Pignatelli</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>B</given-names></name><name><surname>Pritchard</surname><given-names>E</given-names></name><name><surname>Riat</surname><given-names>HS</given-names></name><name><surname>Ritchie</surname><given-names>GRS</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>M</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name><name><surname>Sobral</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Thormann</surname><given-names>A</given-names></name><name><surname>Trevanion</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>S</given-names></name><name><surname>Wilder</surname><given-names>SP</given-names></name><name><surname>Aken</surname><given-names>BL</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Harrow</surname><given-names>J</given-names></name><name><surname>Herrero</surname><given-names>J</given-names></name><name><surname>Hubbard</surname><given-names>TJP</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Kinsella</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Spudich</surname><given-names>G</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Zadissa</surname><given-names>A</given-names></name><name><surname>Searle</surname><given-names>SMJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ensembl 2013</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D48</fpage><lpage>D55</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1236</pub-id><pub-id pub-id-type="pmid">23203987</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Greedy function approximation: a gradient boosting machine</article-title><source>The Annals of Statistics</source><volume>29</volume><elocation-id>3451</elocation-id><pub-id pub-id-type="doi">10.1214/aos/1013203451</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>LZ</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Bernatchez</surname><given-names>C</given-names></name><name><surname>Woodman</surname><given-names>SE</given-names></name><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Futreal</surname><given-names>A</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Loss of ifn-γ pathway genes in tumor cells as a mechanism of resistance to anti-ctla-4 therapy</article-title><source>Cell</source><volume>167</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.069</pub-id><pub-id pub-id-type="pmid">27667683</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gide</surname><given-names>TN</given-names></name><name><surname>Quek</surname><given-names>C</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Tasker</surname><given-names>AT</given-names></name><name><surname>Shang</surname><given-names>P</given-names></name><name><surname>Holst</surname><given-names>J</given-names></name><name><surname>Madore</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>SY</given-names></name><name><surname>Velickovic</surname><given-names>R</given-names></name><name><surname>Wongchenko</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Lo</surname><given-names>S</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Guminski</surname><given-names>A</given-names></name><name><surname>Saw</surname><given-names>RPM</given-names></name><name><surname>Pang</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>HM</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name><name><surname>Silva</surname><given-names>I da</given-names></name><name><surname>Batten</surname><given-names>M</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Wilmott</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Distinct immune cell populations define response to anti-pd-1 monotherapy and anti-pd-1/anti-ctla-4 combined therapy</article-title><source>Cancer Cell</source><volume>35</volume><fpage>238</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.01.003</pub-id><pub-id pub-id-type="pmid">30753825</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glimcher</surname><given-names>LH</given-names></name><name><surname>Kara</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Sequences and factors: a guide to MHC class-II transcription</article-title><source>Annual Review of Immunology</source><volume>10</volume><fpage>13</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1146/annurev.iy.10.040192.000305</pub-id><pub-id pub-id-type="pmid">1590984</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>DeCristo</surname><given-names>MJ</given-names></name><name><surname>Watt</surname><given-names>AC</given-names></name><name><surname>BrinJones</surname><given-names>H</given-names></name><name><surname>Sceneay</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>BB</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Ubellacker</surname><given-names>JM</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Metzger-Filho</surname><given-names>O</given-names></name><name><surname>Hoog</surname><given-names>J</given-names></name><name><surname>Ellis</surname><given-names>MJ</given-names></name><name><surname>Ma</surname><given-names>CX</given-names></name><name><surname>Ramm</surname><given-names>S</given-names></name><name><surname>Krop</surname><given-names>IE</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>McAllister</surname><given-names>SS</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CDK4/6 inhibition triggers anti-tumour immunity</article-title><source>Nature</source><volume>548</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/nature23465</pub-id><pub-id pub-id-type="pmid">28813415</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>C</given-names></name><name><surname>Chilton-MacNeill</surname><given-names>S</given-names></name><name><surname>Zielenska</surname><given-names>M</given-names></name><name><surname>Somers</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas</article-title><source>Human Pathology</source><volume>43</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2011.04.023</pub-id><pub-id pub-id-type="pmid">21813156</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Giannakis</surname><given-names>M</given-names></name><name><surname>Wells</surname><given-names>DK</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name><name><surname>Mu</surname><given-names>XJ</given-names></name><name><surname>Quist</surname><given-names>M</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Nishihara</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>ZR</given-names></name><name><surname>Inamura</surname><given-names>K</given-names></name><name><surname>Morikawa</surname><given-names>T</given-names></name><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Abril-Rodriguez</surname><given-names>G</given-names></name><name><surname>Connolly</surname><given-names>C</given-names></name><name><surname>Escuin-Ordinas</surname><given-names>H</given-names></name><name><surname>Geybels</surname><given-names>MS</given-names></name><name><surname>Grady</surname><given-names>WM</given-names></name><name><surname>Hsu</surname><given-names>L</given-names></name><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Huyghe</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Krystofinski</surname><given-names>P</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Montoya</surname><given-names>DJ</given-names></name><name><surname>Nadel</surname><given-names>BB</given-names></name><name><surname>Pellegrini</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Puig-Saus</surname><given-names>C</given-names></name><name><surname>Quist</surname><given-names>EH</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Salipante</surname><given-names>SJ</given-names></name><name><surname>Shin</surname><given-names>DS</given-names></name><name><surname>Shinbrot</surname><given-names>E</given-names></name><name><surname>Shirts</surname><given-names>B</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Stanford</surname><given-names>JL</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Upfill-Brown</surname><given-names>A</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Zaidi</surname><given-names>SH</given-names></name><name><surname>Zaretsky</surname><given-names>JM</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic mechanisms of immune evasion in colorectal cancer</article-title><source>Cancer Discovery</source><volume>8</volume><fpage>730</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1327</pub-id><pub-id pub-id-type="pmid">29510987</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Onyshchenko</surname><given-names>M</given-names></name><name><surname>Abril-Rodriguez</surname><given-names>G</given-names></name><name><surname>Ross-Macdonald</surname><given-names>P</given-names></name><name><surname>Wind-Rotolo</surname><given-names>M</given-names></name><name><surname>Champhekar</surname><given-names>A</given-names></name><name><surname>Medina</surname><given-names>E</given-names></name><name><surname>Torrejon</surname><given-names>DY</given-names></name><name><surname>Shin</surname><given-names>DS</given-names></name><name><surname>Tran</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Puig-Saus</surname><given-names>C</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Vega-Crespo</surname><given-names>A</given-names></name><name><surname>Quist</surname><given-names>M</given-names></name><name><surname>Martignier</surname><given-names>C</given-names></name><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Johnson</surname><given-names>DB</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Sharfman</surname><given-names>W</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Slingluff</surname><given-names>CL</given-names></name><name><surname>Diab</surname><given-names>A</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Algarra</surname><given-names>SM</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Anagnostou</surname><given-names>V</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name><name><surname>Kalbasi</surname><given-names>A</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma</article-title><source>Cancer Cell</source><volume>38</volume><fpage>500</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.08.005</pub-id><pub-id pub-id-type="pmid">32916126</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Greenwell</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Fastshap: fast approximate Shapley values</data-title><version designator="0.0.7">0.0.7</version><source>R Package</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=fastshap">https://CRAN.R-project.org/package=fastshap</ext-link></element-citation></ref><ref id="bib35"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><source>The Elements of Statistical Learning</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-0-387-84858-7</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heagerty</surname><given-names>PJ</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Survival model predictive accuracy and ROC curves</article-title><source>Biometrics</source><volume>61</volume><fpage>92</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1111/j.0006-341X.2005.030814.x</pub-id><pub-id pub-id-type="pmid">15737082</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Bernabe Caro</surname><given-names>R</given-names></name><name><surname>Zurawski</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Carcereny Costa</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Alexandru</surname><given-names>A</given-names></name><name><surname>Lupinacci</surname><given-names>L</given-names></name><name><surname>de la Mora Jimenez</surname><given-names>E</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Albert</surname><given-names>I</given-names></name><name><surname>Vergnenegre</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Syrigos</surname><given-names>K</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Borghaei</surname><given-names>H</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>O’Byrne</surname><given-names>KJ</given-names></name><name><surname>Geese</surname><given-names>WJ</given-names></name><name><surname>Bhagavatheeswaran</surname><given-names>P</given-names></name><name><surname>Rabindran</surname><given-names>SK</given-names></name><name><surname>Kasinathan</surname><given-names>RS</given-names></name><name><surname>Nathan</surname><given-names>FE</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nivolumab plus ipilimumab in advanced non-small-cell lung cancer</article-title><source>The New England Journal of Medicine</source><volume>381</volume><fpage>2020</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910231</pub-id><pub-id pub-id-type="pmid">31562796</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickson</surname><given-names>PG</given-names></name><name><surname>Doráis</surname><given-names>JA</given-names></name><name><surname>Grow</surname><given-names>EJ</given-names></name><name><surname>Whiddon</surname><given-names>JL</given-names></name><name><surname>Lim</surname><given-names>JW</given-names></name><name><surname>Wike</surname><given-names>CL</given-names></name><name><surname>Weaver</surname><given-names>BD</given-names></name><name><surname>Pflueger</surname><given-names>C</given-names></name><name><surname>Emery</surname><given-names>BR</given-names></name><name><surname>Wilcox</surname><given-names>AL</given-names></name><name><surname>Nix</surname><given-names>DA</given-names></name><name><surname>Peterson</surname><given-names>CM</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name><name><surname>Carrell</surname><given-names>DT</given-names></name><name><surname>Cairns</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons</article-title><source>Nature Genetics</source><volume>49</volume><fpage>925</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1038/ng.3844</pub-id><pub-id pub-id-type="pmid">28459457</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himeda</surname><given-names>CL</given-names></name><name><surname>Jones</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The genetics and epigenetics of facioscapulohumeral muscular dystrophy</article-title><source>Annual Review of Genomics and Human Genetics</source><volume>20</volume><fpage>265</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1146/annurev-genom-083118-014933</pub-id><pub-id pub-id-type="pmid">31018108</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsich</surname><given-names>EM</given-names></name><name><surname>Thuita</surname><given-names>L</given-names></name><name><surname>McNamara</surname><given-names>DM</given-names></name><name><surname>Rogers</surname><given-names>JG</given-names></name><name><surname>Valapour</surname><given-names>M</given-names></name><name><surname>Goldberg</surname><given-names>LR</given-names></name><name><surname>Yancy</surname><given-names>CW</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Ishwaran</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Variables of importance in the scientific registry of transplant recipients database predictive of heart transplant waitlist mortality</article-title><source>American Journal of Transplantation</source><volume>19</volume><fpage>2067</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1111/ajt.15265</pub-id><pub-id pub-id-type="pmid">30659754</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishwaran</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Variable importance in binary regression trees and forests</article-title><source>Electronic Journal of Statistics</source><volume>1</volume><elocation-id>eS039</elocation-id><pub-id pub-id-type="doi">10.1214/07-EJS039</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Kogalur</surname><given-names>UB</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Lauer</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Random survival forests</article-title><source>The Annals of Applied Statistics</source><volume>2</volume><elocation-id>eS169</elocation-id><pub-id pub-id-type="doi">10.1214/08-AOAS169</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Apperson-Hansen</surname><given-names>C</given-names></name><name><surname>Rice</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A novel approach to cancer staging: application to esophageal cancer</article-title><source>Biostatistics</source><volume>10</volume><fpage>603</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxp016</pub-id><pub-id pub-id-type="pmid">19502615</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Kogalur</surname><given-names>UB</given-names></name><name><surname>Gorodeski</surname><given-names>EZ</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name><name><surname>Lauer</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>High-dimensional variable selection for survival data</article-title><source>Journal of the American Statistical Association</source><volume>105</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1198/jasa.2009.tm08622</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Kogalur</surname><given-names>UB</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Minn</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Random survival forests for high‐dimensional data</article-title><source>Statistical Analysis and Data Mining</source><volume>4</volume><fpage>115</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/sam.10103</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Standard errors and confidence intervals for variable importance in random forest regression, classification, and survival</article-title><source>Statistics in Medicine</source><volume>38</volume><fpage>558</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1002/sim.7803</pub-id><pub-id pub-id-type="pmid">29869423</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Sung</surname><given-names>YS</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas</article-title><source>Genes, Chromosomes &amp; Cancer</source><volume>51</volume><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/gcc.20945</pub-id><pub-id pub-id-type="pmid">22072439</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janitza</surname><given-names>S</given-names></name><name><surname>Hornung</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>On the overestimation of random forest’s out-of-bag error</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0201904</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0201904</pub-id><pub-id pub-id-type="pmid">30080866</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerby-Arnon</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Cuoco</surname><given-names>MS</given-names></name><name><surname>Rodman</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>MJ</given-names></name><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Leeson</surname><given-names>R</given-names></name><name><surname>Kanodia</surname><given-names>A</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Rabasha</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Margolais</surname><given-names>C</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Buchbinder</surname><given-names>EI</given-names></name><name><surname>Haq</surname><given-names>R</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Boland</surname><given-names>GM</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Miao</surname><given-names>B</given-names></name><name><surname>Moll</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Jenkins</surname><given-names>RW</given-names></name><name><surname>Thummalapalli</surname><given-names>R</given-names></name><name><surname>Kowalczyk</surname><given-names>MS</given-names></name><name><surname>Cañadas</surname><given-names>I</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Cartwright</surname><given-names>ANR</given-names></name><name><surname>Luoma</surname><given-names>AM</given-names></name><name><surname>Malu</surname><given-names>S</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Bernatchez</surname><given-names>C</given-names></name><name><surname>Forget</surname><given-names>MA</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Wucherpfennig</surname><given-names>K</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Rotem</surname><given-names>A</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A cancer cell program promotes t cell exclusion and resistance to checkpoint blockade</article-title><source>Cell</source><volume>175</volume><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.006</pub-id><pub-id pub-id-type="pmid">30388455</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Sahu</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Traugh</surname><given-names>N</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1550</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0136-1</pub-id><pub-id pub-id-type="pmid">30127393</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>AM</given-names></name><name><surname>Bullock</surname><given-names>BL</given-names></name><name><surname>Neuwelt</surname><given-names>AJ</given-names></name><name><surname>Poczobutt</surname><given-names>JM</given-names></name><name><surname>Kaspar</surname><given-names>RE</given-names></name><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>Kwak</surname><given-names>JW</given-names></name><name><surname>Hopp</surname><given-names>K</given-names></name><name><surname>Weiser-Evans</surname><given-names>MCM</given-names></name><name><surname>Heasley</surname><given-names>LE</given-names></name><name><surname>Schenk</surname><given-names>EL</given-names></name><name><surname>Clambey</surname><given-names>ET</given-names></name><name><surname>Nemenoff</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cancer cell-intrinsic expression of mhc class ii regulates the immune microenvironment and response to anti-pd-1 therapy in lung adenocarcinoma</article-title><source>Journal of Immunology</source><volume>204</volume><fpage>2295</fpage><lpage>2307</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900778</pub-id><pub-id pub-id-type="pmid">32179637</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalbasi</surname><given-names>A</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tumour-intrinsic resistance to immune checkpoint blockade</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0218-4</pub-id><pub-id pub-id-type="pmid">31570880</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kassambara</surname><given-names>A</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Biecek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Survminer: drawing survival curves using “Ggplot2</data-title><version designator="0.4.9">0.4.9</version><source>R Package</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survminer">https://CRAN.R-project.org/package=survminer</ext-link></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>ET</given-names></name><name><surname>Airoldi</surname><given-names>EM</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Analysis and design of RNA sequencing experiments for identifying isoform regulation</article-title><source>Nature Methods</source><volume>7</volume><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1528</pub-id><pub-id pub-id-type="pmid">21057496</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura-Saito</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Kawaguchi</surname><given-names>N</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Mukai</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>T</given-names></name><name><surname>Motoi</surname><given-names>T</given-names></name><name><surname>Fukayama</surname><given-names>M</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Takizawa</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fusion between CIC and DUX4 up-regulates PEA3 family genes in ewing-like sarcomas with t(4;19)(q35;q13) translocation</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>2125</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl136</pub-id><pub-id pub-id-type="pmid">16717057</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>O</given-names></name><name><surname>Kee</surname><given-names>D</given-names></name><name><surname>Nagrial</surname><given-names>A</given-names></name><name><surname>Markman</surname><given-names>B</given-names></name><name><surname>Underhill</surname><given-names>C</given-names></name><name><surname>Michael</surname><given-names>M</given-names></name><name><surname>Jackett</surname><given-names>L</given-names></name><name><surname>Lum</surname><given-names>C</given-names></name><name><surname>Behren</surname><given-names>A</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>Tebbutt</surname><given-names>NC</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial</article-title><source>JAMA Oncology</source><volume>6</volume><fpage>1405</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.2814</pub-id><pub-id pub-id-type="pmid">32729929</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>M</given-names></name><name><surname>Kasinath</surname><given-names>P</given-names></name><name><surname>High</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Teply</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors</article-title><source>JCO Oncology Practice</source><volume>18</volume><fpage>e175</fpage><lpage>e182</lpage><pub-id pub-id-type="doi">10.1200/OP.20.01055</pub-id><pub-id pub-id-type="pmid">34351819</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Caret: classification and regression training</data-title><version designator="6.0-93">6.0-93</version><source>R Package</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=caret">https://CRAN.R-project.org/package=caret</ext-link></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pop</surname><given-names>M</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome</article-title><source>Genome Biology</source><volume>10</volume><elocation-id>R25</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2009-10-3-r25</pub-id><pub-id pub-id-type="pmid">19261174</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Cowey</surname><given-names>CL</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Wagstaff</surname><given-names>J</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Ferrucci</surname><given-names>PF</given-names></name><name><surname>Smylie</surname><given-names>M</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Márquez-Rodas</surname><given-names>I</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Guidoboni</surname><given-names>M</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Schöffski</surname><given-names>P</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Lebbé</surname><given-names>C</given-names></name><name><surname>McArthur</surname><given-names>G</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Daniels</surname><given-names>GA</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Bastholt</surname><given-names>L</given-names></name><name><surname>Rizzo</surname><given-names>JI</given-names></name><name><surname>Balogh</surname><given-names>A</given-names></name><name><surname>Moshyk</surname><given-names>A</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Five-year survival with combined nivolumab and ipilimumab in advanced melanoma</article-title><source>The New England Journal of Medicine</source><volume>381</volume><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910836</pub-id><pub-id pub-id-type="pmid">31562797</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><name><surname>Navarro</surname><given-names>A</given-names></name><name><surname>Lianoglou</surname><given-names>S</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name><name><surname>Totpal</surname><given-names>K</given-names></name><name><surname>Sanders</surname><given-names>L</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Caplazi</surname><given-names>P</given-names></name><name><surname>McBride</surname><given-names>J</given-names></name><name><surname>Chiu</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>R</given-names></name><name><surname>Grogan</surname><given-names>J</given-names></name><name><surname>Javinal</surname><given-names>V</given-names></name><name><surname>Yauch</surname><given-names>R</given-names></name><name><surname>Irving</surname><given-names>B</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14572</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14572</pub-id><pub-id pub-id-type="pmid">28220772</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Shklovskaya</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>SY</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Pedersen</surname><given-names>B</given-names></name><name><surname>Irvine</surname><given-names>M</given-names></name><name><surname>Alavi</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>JYH</given-names></name><name><surname>Strbenac</surname><given-names>D</given-names></name><name><surname>Saw</surname><given-names>RPM</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Wilmott</surname><given-names>JS</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Kefford</surname><given-names>RF</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1897</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15726-7</pub-id><pub-id pub-id-type="pmid">32312968</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/map format and samtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Dewey</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>R</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Cao</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>CQ</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>CM</given-names></name><name><surname>Jokitalo</surname><given-names>E</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>HB</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The tumor suppressor PTEN has a critical role in antiviral innate immunity</article-title><source>Nature Immunology</source><volume>17</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1038/ni.3311</pub-id><pub-id pub-id-type="pmid">26692175</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilljebjörn</surname><given-names>H</given-names></name><name><surname>Henningsson</surname><given-names>R</given-names></name><name><surname>Hyrenius-Wittsten</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>L</given-names></name><name><surname>Orsmark-Pietras</surname><given-names>C</given-names></name><name><surname>von Palffy</surname><given-names>S</given-names></name><name><surname>Askmyr</surname><given-names>M</given-names></name><name><surname>Rissler</surname><given-names>M</given-names></name><name><surname>Schrappe</surname><given-names>M</given-names></name><name><surname>Cario</surname><given-names>G</given-names></name><name><surname>Castor</surname><given-names>A</given-names></name><name><surname>Pronk</surname><given-names>CJH</given-names></name><name><surname>Behrendtz</surname><given-names>M</given-names></name><name><surname>Mitelman</surname><given-names>F</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Paulsson</surname><given-names>K</given-names></name><name><surname>Andersson</surname><given-names>AK</given-names></name><name><surname>Fontes</surname><given-names>M</given-names></name><name><surname>Fioretos</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11790</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11790</pub-id><pub-id pub-id-type="pmid">27265895</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Hurt</surname><given-names>EM</given-names></name><name><surname>Green</surname><given-names>MD</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Vatan</surname><given-names>L</given-names></name><name><surname>Szeliga</surname><given-names>W</given-names></name><name><surname>Herbst</surname><given-names>R</given-names></name><name><surname>Harms</surname><given-names>PW</given-names></name><name><surname>Fecher</surname><given-names>LA</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Lawrence</surname><given-names>TS</given-names></name><name><surname>Wicha</surname><given-names>M</given-names></name><name><surname>Hamanishi</surname><given-names>J</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Kryczek</surname><given-names>I</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression</article-title><source>The Journal of Clinical Investigation</source><volume>128</volume><fpage>805</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1172/JCI96113</pub-id><pub-id pub-id-type="pmid">29337305</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>BY</given-names></name><name><surname>Zhang</surname><given-names>WN</given-names></name><name><surname>Huang</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>BS</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>JF</given-names></name><name><surname>Wang</surname><given-names>MJ</given-names></name><name><surname>Dai</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>ZG</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>YM</given-names></name><name><surname>Weng</surname><given-names>XQ</given-names></name><name><surname>Shen</surname><given-names>ZX</given-names></name><name><surname>Li</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>XJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>XQ</given-names></name><name><surname>Zhang</surname><given-names>WG</given-names></name><name><surname>Yan</surname><given-names>JS</given-names></name><name><surname>Hu</surname><given-names>JD</given-names></name><name><surname>Shen</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>LJ</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>RB</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>KK</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Mi</surname><given-names>JQ</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Tang</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic profiling of adult and pediatric b-cell acute lymphoblastic leukemia</article-title><source>EBioMedicine</source><volume>8</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.04.038</pub-id><pub-id pub-id-type="pmid">27428428</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Unified Approach to Interpreting Model Predictions</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.48550/arXiv.1705.07874">https://doi.org/10.48550/arXiv.1705.07874</ext-link></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>SM</given-names></name><name><surname>Erion</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>DeGrave</surname><given-names>A</given-names></name><name><surname>Prutkin</surname><given-names>JM</given-names></name><name><surname>Nair</surname><given-names>B</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Himmelfarb</surname><given-names>J</given-names></name><name><surname>Bansal</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>From local explanations to global understanding with explainable ai for trees</article-title><source>Nature Machine Intelligence</source><volume>2</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/s42256-019-0138-9</pub-id><pub-id pub-id-type="pmid">32607472</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Maksymiuk</surname><given-names>S</given-names></name><name><surname>Gosiewska</surname><given-names>A</given-names></name><name><surname>Biecek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Landscape of R Packages for eXplainable Artificial Intelligence</article-title><source>arXiv</source><pub-id pub-id-type="doi">10.48550/arXiv.2009.13248</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Nickles</surname><given-names>D</given-names></name><name><surname>Castiglioni</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kadel</surname><given-names>EE</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Astarita</surname><given-names>JL</given-names></name><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Banchereau</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Chalouni</surname><given-names>C</given-names></name><name><surname>Ziai</surname><given-names>J</given-names></name><name><surname>Şenbabaoğlu</surname><given-names>Y</given-names></name><name><surname>Santoro</surname><given-names>S</given-names></name><name><surname>Sheinson</surname><given-names>D</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Giltnane</surname><given-names>JM</given-names></name><name><surname>Pierce</surname><given-names>AA</given-names></name><name><surname>Mesh</surname><given-names>K</given-names></name><name><surname>Lianoglou</surname><given-names>S</given-names></name><name><surname>Riegler</surname><given-names>J</given-names></name><name><surname>Carano</surname><given-names>RAD</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Höglund</surname><given-names>M</given-names></name><name><surname>Somarriba</surname><given-names>L</given-names></name><name><surname>Halligan</surname><given-names>DL</given-names></name><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Derleth</surname><given-names>C</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells</article-title><source>Nature</source><volume>554</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/nature25501</pub-id><pub-id pub-id-type="pmid">29443960</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masternak</surname><given-names>K</given-names></name><name><surname>Muhlethaler-Mottet</surname><given-names>A</given-names></name><name><surname>Villard</surname><given-names>J</given-names></name><name><surname>Zufferey</surname><given-names>M</given-names></name><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>1156</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1101/gad.14.9.1156</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Furness</surname><given-names>AJS</given-names></name><name><surname>Rosenthal</surname><given-names>R</given-names></name><name><surname>Ramskov</surname><given-names>S</given-names></name><name><surname>Lyngaa</surname><given-names>R</given-names></name><name><surname>Saini</surname><given-names>SK</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>GA</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Hiley</surname><given-names>CT</given-names></name><name><surname>Watkins</surname><given-names>TBK</given-names></name><name><surname>Shafi</surname><given-names>S</given-names></name><name><surname>Murugaesu</surname><given-names>N</given-names></name><name><surname>Mitter</surname><given-names>R</given-names></name><name><surname>Akarca</surname><given-names>AU</given-names></name><name><surname>Linares</surname><given-names>J</given-names></name><name><surname>Marafioti</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>JY</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Snyder</surname><given-names>A</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Hadrup</surname><given-names>SR</given-names></name><name><surname>Quezada</surname><given-names>SA</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title><source>Science</source><volume>351</volume><fpage>1463</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1126/science.aaf1490</pub-id><pub-id pub-id-type="pmid">26940869</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>LR</given-names></name><name><surname>Zweig</surname><given-names>AS</given-names></name><name><surname>Hinrichs</surname><given-names>AS</given-names></name><name><surname>Karolchik</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>RM</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Sloan</surname><given-names>CA</given-names></name><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Roe</surname><given-names>G</given-names></name><name><surname>Rhead</surname><given-names>B</given-names></name><name><surname>Raney</surname><given-names>BJ</given-names></name><name><surname>Pohl</surname><given-names>A</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>BT</given-names></name><name><surname>Learned</surname><given-names>K</given-names></name><name><surname>Kirkup</surname><given-names>V</given-names></name><name><surname>Hsu</surname><given-names>F</given-names></name><name><surname>Heitner</surname><given-names>S</given-names></name><name><surname>Harte</surname><given-names>RA</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name><name><surname>Guruvadoo</surname><given-names>L</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name><name><surname>Giardine</surname><given-names>BM</given-names></name><name><surname>Fujita</surname><given-names>PA</given-names></name><name><surname>Dreszer</surname><given-names>TR</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Cline</surname><given-names>MS</given-names></name><name><surname>Clawson</surname><given-names>H</given-names></name><name><surname>Barber</surname><given-names>GP</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The UCSC genome browser database: extensions and updates 2013</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D64</fpage><lpage>D69</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1048</pub-id><pub-id pub-id-type="pmid">23155063</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Bias of the random forest out-of-bag (oob) error for certain input parameters</article-title><source>Open Journal of Statistics</source><volume>01</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.4236/ojs.2011.13024</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>UB</given-names></name><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Gerds</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Evaluating random forests for survival analysis using prediction error curves</article-title><source>Journal of Statistical Software</source><volume>50</volume><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.18637/jss.v050.i11</pub-id><pub-id pub-id-type="pmid">25317082</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>McCue</surname><given-names>K</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mapping and quantifying mammalian transcriptomes by RNA-Seq</article-title><source>Nature Methods</source><volume>5</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id><pub-id pub-id-type="pmid">18516045</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Hammers</surname><given-names>HJ</given-names></name><name><surname>Srinivas</surname><given-names>S</given-names></name><name><surname>Tykodi</surname><given-names>SS</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Plimack</surname><given-names>ER</given-names></name><name><surname>Procopio</surname><given-names>G</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>Gurney</surname><given-names>H</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Richardet</surname><given-names>M</given-names></name><name><surname>Peltola</surname><given-names>K</given-names></name><name><surname>Alva</surname><given-names>AS</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><name><surname>Wagstaff</surname><given-names>J</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Fukasawa</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>Y</given-names></name><name><surname>Gauler</surname><given-names>TC</given-names></name><name><surname>Kollmannsberger</surname><given-names>CK</given-names></name><name><surname>Schutz</surname><given-names>FA</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>McHenry</surname><given-names>MB</given-names></name><name><surname>Saggi</surname><given-names>SS</given-names></name><name><surname>Tannir</surname><given-names>NM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial</article-title><source>Cancer</source><volume>126</volume><fpage>4156</fpage><lpage>4167</lpage><pub-id pub-id-type="doi">10.1002/cncr.33033</pub-id><pub-id pub-id-type="pmid">32673417</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarsheth</surname><given-names>N</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>559</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.49</pub-id><pub-id pub-id-type="pmid">28555670</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newell</surname><given-names>F</given-names></name><name><surname>Pires da Silva</surname><given-names>I</given-names></name><name><surname>Johansson</surname><given-names>PA</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Wilmott</surname><given-names>JS</given-names></name><name><surname>Addala</surname><given-names>V</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name><name><surname>Nones</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>JJ</given-names></name><name><surname>Lakis</surname><given-names>V</given-names></name><name><surname>Kazakoff</surname><given-names>SH</given-names></name><name><surname>Mukhopadhyay</surname><given-names>P</given-names></name><name><surname>Ferguson</surname><given-names>PM</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Koufariotis</surname><given-names>LT</given-names></name><name><surname>Wood</surname><given-names>S</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Spillane</surname><given-names>AJ</given-names></name><name><surname>Saw</surname><given-names>RPM</given-names></name><name><surname>Shannon</surname><given-names>KF</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Mann</surname><given-names>GJ</given-names></name><name><surname>Hayward</surname><given-names>NK</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance</article-title><source>Cancer Cell</source><volume>40</volume><fpage>88</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.11.012</pub-id><pub-id pub-id-type="pmid">34951955</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Ramsay</surname><given-names>L</given-names></name><name><surname>Ahanfeshar-Adams</surname><given-names>M</given-names></name><name><surname>Lajoie</surname><given-names>M</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Alain</surname><given-names>T</given-names></name><name><surname>Watson</surname><given-names>IR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mutations in the ifnγ-jak-stat pathway causing resistance to immune checkpoint inhibitors in melanoma increase sensitivity to oncolytic virus treatment</article-title><source>Clinical Cancer Research</source><volume>27</volume><fpage>3432</fpage><lpage>3442</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-3365</pub-id><pub-id pub-id-type="pmid">33593882</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>JP</given-names></name><name><surname>Gubin</surname><given-names>MM</given-names></name><name><surname>Arthur</surname><given-names>CD</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Hundal</surname><given-names>J</given-names></name><name><surname>Selby</surname><given-names>MJ</given-names></name><name><surname>Graziano</surname><given-names>RF</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Temporally distinct pd-l1 expression by tumor and host cells contributes to immune escape</article-title><source>Cancer Immunology Research</source><volume>5</volume><fpage>106</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0391</pub-id><pub-id pub-id-type="pmid">28073774</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Brien</surname><given-names>RC</given-names></name><name><surname>Ishwaran</surname><given-names>H</given-names></name><name><surname>Szczotka-Flynn</surname><given-names>LB</given-names></name><name><surname>Lass</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Random survival forests analysis of intraoperative complications as predictors of descemet stripping automated endothelial keratoplasty graft failure in the cornea preservation time study</article-title><source>JAMA Ophthalmology</source><volume>139</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2020.5743</pub-id><pub-id pub-id-type="pmid">33355637</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>JQ</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Malu</surname><given-names>S</given-names></name><name><surname>Creasy</surname><given-names>C</given-names></name><name><surname>Tetzlaff</surname><given-names>MT</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>McKenzie</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Mbofung</surname><given-names>R</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Torres-Cabala</surname><given-names>CA</given-names></name><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Tieu</surname><given-names>TN</given-names></name><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Bernatchez</surname><given-names>C</given-names></name><name><surname>Forget</surname><given-names>MA</given-names></name><name><surname>Haymaker</surname><given-names>C</given-names></name><name><surname>Amaria</surname><given-names>R</given-names></name><name><surname>McQuade</surname><given-names>JL</given-names></name><name><surname>Glitza</surname><given-names>IC</given-names></name><name><surname>Cascone</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>HS</given-names></name><name><surname>Kwong</surname><given-names>LN</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Bassett</surname><given-names>RL</given-names></name><name><surname>Bosenberg</surname><given-names>MW</given-names></name><name><surname>Woodman</surname><given-names>SE</given-names></name><name><surname>Overwijk</surname><given-names>WW</given-names></name><name><surname>Lizée</surname><given-names>G</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Radvanyi</surname><given-names>L</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Loss of PTEN promotes resistance to t cell-mediated immunotherapy</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>202</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0283</pub-id><pub-id pub-id-type="pmid">26645196</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Eder</surname><given-names>JP</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Braiteh</surname><given-names>FS</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Cruz</surname><given-names>C</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Teng</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Boyd</surname><given-names>Z</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Vogelzang</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer</article-title><source>Nature</source><volume>515</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/nature13904</pub-id><pub-id pub-id-type="pmid">25428503</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preussner</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Sreenivasan</surname><given-names>K</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Engleitner</surname><given-names>T</given-names></name><name><surname>Künne</surname><given-names>C</given-names></name><name><surname>Glatzel</surname><given-names>M</given-names></name><name><surname>Rad</surname><given-names>R</given-names></name><name><surname>Looso</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oncogenic amplification of zygotic dux factors in regenerating p53-deficient muscle stem cells defines a molecular cancer subtype</article-title><source>Cell Stem Cell</source><volume>23</volume><fpage>794</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.10.011</pub-id><pub-id pub-id-type="pmid">30449715</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kham</surname><given-names>SKY</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Goodings</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>TN</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Moriyama</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Quah</surname><given-names>TC</given-names></name><name><surname>Ariffin</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>AM</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Bhojwani</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Pui</surname><given-names>CH</given-names></name><name><surname>Yeoh</surname><given-names>AEJ</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP</article-title><source>Genome Research</source><volume>27</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1101/gr.209163.116</pub-id><pub-id pub-id-type="pmid">27903646</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2022">2022</year><data-title>R: A language and environment for statistical computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Atkinson</surname><given-names>V</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>WH</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>Fisher</surname><given-names>R</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Tsoi</surname><given-names>J</given-names></name><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Mookerjee</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Ghori</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>BH</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma</article-title><source>Nature Medicine</source><volume>25</volume><fpage>936</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0476-5</pub-id><pub-id pub-id-type="pmid">31171879</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>Oshlack</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A scaling normalization method for differential expression analysis of RNA-seq data</article-title><source>Genome Biology</source><volume>11</volume><elocation-id>R25</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2010-11-3-r25</pub-id><pub-id pub-id-type="pmid">20196867</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Cobain</surname><given-names>E</given-names></name><name><surname>Everett</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Rabban</surname><given-names>E</given-names></name><name><surname>Kumar-Sinha</surname><given-names>C</given-names></name><name><surname>Raymond</surname><given-names>V</given-names></name><name><surname>Schuetze</surname><given-names>S</given-names></name><name><surname>Alva</surname><given-names>A</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Chugh</surname><given-names>R</given-names></name><name><surname>Worden</surname><given-names>F</given-names></name><name><surname>Zalupski</surname><given-names>MM</given-names></name><name><surname>Innis</surname><given-names>J</given-names></name><name><surname>Mody</surname><given-names>RJ</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Lucas</surname><given-names>D</given-names></name><name><surname>Baker</surname><given-names>LH</given-names></name><name><surname>Ramnath</surname><given-names>N</given-names></name><name><surname>Schott</surname><given-names>AF</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><name><surname>Vijai</surname><given-names>J</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Stoffel</surname><given-names>EM</given-names></name><name><surname>Roberts</surname><given-names>JS</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>Cieślik</surname><given-names>M</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Integrative clinical genomics of metastatic cancer</article-title><source>Nature</source><volume>548</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/nature23306</pub-id><pub-id pub-id-type="pmid">28783718</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>PA</given-names></name><name><surname>Furuta</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The ins and outs of MHC class II-mediated antigen processing and presentation</article-title><source>Nature Reviews. Immunology</source><volume>15</volume><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/nri3818</pub-id><pub-id pub-id-type="pmid">25720354</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Hoffman-Censits</surname><given-names>J</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>van der Heijden</surname><given-names>MS</given-names></name><name><surname>Balar</surname><given-names>AV</given-names></name><name><surname>Necchi</surname><given-names>A</given-names></name><name><surname>Dawson</surname><given-names>N</given-names></name><name><surname>O’Donnell</surname><given-names>PH</given-names></name><name><surname>Balmanoukian</surname><given-names>A</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Srinivas</surname><given-names>S</given-names></name><name><surname>Retz</surname><given-names>MM</given-names></name><name><surname>Grivas</surname><given-names>P</given-names></name><name><surname>Joseph</surname><given-names>RW</given-names></name><name><surname>Galsky</surname><given-names>MD</given-names></name><name><surname>Fleming</surname><given-names>MT</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Perez-Gracia</surname><given-names>JL</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Canil</surname><given-names>C</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Bajorin</surname><given-names>D</given-names></name><name><surname>Nickles</surname><given-names>D</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Frampton</surname><given-names>GM</given-names></name><name><surname>Cui</surname><given-names>N</given-names></name><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Abidoye</surname><given-names>O</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Dreicer</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial</article-title><source>The Lancet</source><volume>387</volume><fpage>1909</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00561-4</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozeman</surname><given-names>EA</given-names></name><name><surname>Hoefsmit</surname><given-names>EP</given-names></name><name><surname>Reijers</surname><given-names>ILM</given-names></name><name><surname>Saw</surname><given-names>RPM</given-names></name><name><surname>Versluis</surname><given-names>JM</given-names></name><name><surname>Krijgsman</surname><given-names>O</given-names></name><name><surname>Dimitriadis</surname><given-names>P</given-names></name><name><surname>Sikorska</surname><given-names>K</given-names></name><name><surname>van de Wiel</surname><given-names>BA</given-names></name><name><surname>Eriksson</surname><given-names>H</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Torres Acosta</surname><given-names>A</given-names></name><name><surname>Grijpink-Ongering</surname><given-names>LG</given-names></name><name><surname>Shannon</surname><given-names>K</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Stretch</surname><given-names>J</given-names></name><name><surname>Ch’ng</surname><given-names>S</given-names></name><name><surname>Nieweg</surname><given-names>OE</given-names></name><name><surname>Mallo</surname><given-names>HA</given-names></name><name><surname>Adriaansz</surname><given-names>S</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>Cornelissen</surname><given-names>S</given-names></name><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>Klop</surname><given-names>WMC</given-names></name><name><surname>Zuur</surname><given-names>CL</given-names></name><name><surname>van Houdt</surname><given-names>WJ</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name><name><surname>Spillane</surname><given-names>AJ</given-names></name><name><surname>van Akkooi</surname><given-names>ACJ</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Schumacher</surname><given-names>TNM</given-names></name><name><surname>Menzies</surname><given-names>AM</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma</article-title><source>Nature Medicine</source><volume>27</volume><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01211-7</pub-id><pub-id pub-id-type="pmid">33558721</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sade-Feldman</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Rooney</surname><given-names>MS</given-names></name><name><surname>Barzily-Rokni</surname><given-names>M</given-names></name><name><surname>Eliane</surname><given-names>JP</given-names></name><name><surname>Bjorgaard</surname><given-names>SL</given-names></name><name><surname>Hammond</surname><given-names>MR</given-names></name><name><surname>Vitzthum</surname><given-names>H</given-names></name><name><surname>Blackmon</surname><given-names>SM</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Hazar-Rethinam</surname><given-names>M</given-names></name><name><surname>Nadres</surname><given-names>BA</given-names></name><name><surname>Van Seventer</surname><given-names>EE</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Yizhak</surname><given-names>K</given-names></name><name><surname>Ray</surname><given-names>JP</given-names></name><name><surname>Rosebrock</surname><given-names>D</given-names></name><name><surname>Livitz</surname><given-names>D</given-names></name><name><surname>Adalsteinsson</surname><given-names>V</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Duncan</surname><given-names>LM</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Corcoran</surname><given-names>RB</given-names></name><name><surname>Lawrence</surname><given-names>DP</given-names></name><name><surname>Stemmer-Rachamimov</surname><given-names>A</given-names></name><name><surname>Boland</surname><given-names>GM</given-names></name><name><surname>Landau</surname><given-names>DA</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Resistance to checkpoint blockade therapy through inactivation of antigen presentation</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1136</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01062-w</pub-id><pub-id pub-id-type="pmid">29070816</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaer</surname><given-names>DA</given-names></name><name><surname>Beckmann</surname><given-names>RP</given-names></name><name><surname>Dempsey</surname><given-names>JA</given-names></name><name><surname>Huber</surname><given-names>L</given-names></name><name><surname>Forest</surname><given-names>A</given-names></name><name><surname>Amaladas</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Rasmussen</surname><given-names>ER</given-names></name><name><surname>Chin</surname><given-names>D</given-names></name><name><surname>Capen</surname><given-names>A</given-names></name><name><surname>Carpenito</surname><given-names>C</given-names></name><name><surname>Staschke</surname><given-names>KA</given-names></name><name><surname>Chung</surname><given-names>LA</given-names></name><name><surname>Litchfield</surname><given-names>LM</given-names></name><name><surname>Merzoug</surname><given-names>FF</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Iversen</surname><given-names>PW</given-names></name><name><surname>Buchanan</surname><given-names>S</given-names></name><name><surname>de Dios</surname><given-names>A</given-names></name><name><surname>Novosiadly</surname><given-names>RD</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The CDK4/6 inhibitor abemaciclib induces a t cell inflamed tumor microenvironment and enhances the efficacy of pd-l1 checkpoint blockade</article-title><source>Cell Reports</source><volume>22</volume><fpage>2978</fpage><lpage>2994</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.02.053</pub-id><pub-id pub-id-type="pmid">29539425</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Gill</surname><given-names>RR</given-names></name><name><surname>Widick</surname><given-names>P</given-names></name><name><surname>Bindal</surname><given-names>P</given-names></name><name><surname>McDonald</surname><given-names>DC</given-names></name><name><surname>Shea</surname><given-names>M</given-names></name><name><surname>Rangachari</surname><given-names>D</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy</article-title><source>JAMA Network Open</source><volume>4</volume><elocation-id>e2037120</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.37120</pub-id><pub-id pub-id-type="pmid">33570575</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semeraro</surname><given-names>F</given-names></name><name><surname>Parrinello</surname><given-names>G</given-names></name><name><surname>Cancarini</surname><given-names>A</given-names></name><name><surname>Pasquini</surname><given-names>L</given-names></name><name><surname>Zarra</surname><given-names>E</given-names></name><name><surname>Cimino</surname><given-names>A</given-names></name><name><surname>Cancarini</surname><given-names>G</given-names></name><name><surname>Valentini</surname><given-names>U</given-names></name><name><surname>Costagliola</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Predicting the risk of diabetic retinopathy in type 2 diabetic patients</article-title><source>Journal of Diabetes and Its Complications</source><volume>25</volume><fpage>292</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2010.12.002</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shapley</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="1953">1953</year><chapter-title>A value for N-person games</chapter-title><person-group person-group-type="editor"><name><surname>Kuhn</surname><given-names>H</given-names></name><name><surname>Tucker</surname><given-names>A</given-names></name></person-group><source>Contributions to the Theory of Games (AM-28), Volume II</source><publisher-name>Princeton University Press</publisher-name><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1515/9781400881970</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>W</given-names></name><name><surname>LaFleur</surname><given-names>MW</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chakravarthy</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>JR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>PH</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>De Carvalho</surname><given-names>DD</given-names></name><name><surname>He</surname><given-names>HH</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade</article-title><source>Cell</source><volume>174</volume><fpage>549</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.05.052</pub-id><pub-id pub-id-type="pmid">29937226</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sievert</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>Interactive Web-Based Data Visualization with R, Plotly, and Shiny</source><publisher-name>Chapman and Hall/CRC</publisher-name><pub-id pub-id-type="doi">10.1201/9780429447273</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>L</given-names></name><name><surname>Geng</surname><given-names>LN</given-names></name><name><surname>Lemmers</surname><given-names>R</given-names></name><name><surname>Kyba</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>CB</given-names></name><name><surname>Nelson</surname><given-names>AM</given-names></name><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Filippova</surname><given-names>GN</given-names></name><name><surname>van der Maarel</surname><given-names>SM</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name><name><surname>Miller</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene</article-title><source>PLOS Genetics</source><volume>6</volume><elocation-id>e1001181</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001181</pub-id><pub-id pub-id-type="pmid">21060811</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spens</surname><given-names>AE</given-names></name><name><surname>Sutliff</surname><given-names>NA</given-names></name><name><surname>Bennett</surname><given-names>SR</given-names></name><name><surname>Campbell</surname><given-names>AE</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Human DUX4 and mouse Dux interact with STAT1 and broadly inhibit interferon-stimulated gene induction</article-title><source>eLife</source><volume>12</volume><elocation-id>e82057</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.82057</pub-id><pub-id pub-id-type="pmid">37092726</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity</article-title><source>Nature</source><volume>523</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/nature14404</pub-id><pub-id pub-id-type="pmid">25970248</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Otten</surname><given-names>LA</given-names></name><name><surname>Zufferey</surname><given-names>M</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)</article-title><source>Cell</source><volume>75</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">8402893</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Siegrist</surname><given-names>CA</given-names></name><name><surname>Mottet</surname><given-names>A</given-names></name><name><surname>Lisowska-Grospierre</surname><given-names>B</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA</article-title><source>Science</source><volume>265</volume><fpage>106</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1126/science.8016643</pub-id><pub-id pub-id-type="pmid">8016643</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Paschold</surname><given-names>L</given-names></name><name><surname>Tintelnot</surname><given-names>J</given-names></name><name><surname>Goekkurt</surname><given-names>E</given-names></name><name><surname>Henkes</surname><given-names>SS</given-names></name><name><surname>Simnica</surname><given-names>D</given-names></name><name><surname>Schultheiss</surname><given-names>C</given-names></name><name><surname>Willscher</surname><given-names>E</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Wickenhauser</surname><given-names>C</given-names></name><name><surname>Thuss-Patience</surname><given-names>P</given-names></name><name><surname>Lorenzen</surname><given-names>S</given-names></name><name><surname>Ettrich</surname><given-names>T</given-names></name><name><surname>Riera-Knorrenschild</surname><given-names>J</given-names></name><name><surname>Jacobasch</surname><given-names>L</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Kubicka</surname><given-names>S</given-names></name><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Reinacher-Schick</surname><given-names>A</given-names></name><name><surname>Pink</surname><given-names>D</given-names></name><name><surname>Sinn</surname><given-names>M</given-names></name><name><surname>Lindig</surname><given-names>U</given-names></name><name><surname>Hiegl</surname><given-names>W</given-names></name><name><surname>Hinke</surname><given-names>A</given-names></name><name><surname>Hegewisch-Becker</surname><given-names>S</given-names></name><name><surname>Binder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Efficacy of ipilimumab vs folfox in combination with nivolumab and trastuzumab in patients with previously untreated erbb2-positive esophagogastric adenocarcinoma: the aio intega randomized clinical trial</article-title><source>JAMA Oncology</source><volume>8</volume><fpage>1150</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.2228</pub-id><pub-id pub-id-type="pmid">35737383</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Štrumbelj</surname><given-names>E</given-names></name><name><surname>Kononenko</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Explaining prediction models and individual predictions with feature contributions</article-title><source>Knowledge and Information Systems</source><volume>41</volume><fpage>647</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1007/s10115-013-0679-x</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Real</surname><given-names>B</given-names></name><name><surname>Heeke</surname><given-names>C</given-names></name><name><surname>Bielefeld</surname><given-names>N</given-names></name><name><surname>Maβen</surname><given-names>S</given-names></name><name><surname>Horn</surname><given-names>S</given-names></name><name><surname>Moll</surname><given-names>I</given-names></name><name><surname>Maltaner</surname><given-names>R</given-names></name><name><surname>Horn</surname><given-names>PA</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Sabbatino</surname><given-names>F</given-names></name><name><surname>Lennerz</surname><given-names>V</given-names></name><name><surname>Kloor</surname><given-names>M</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Falk</surname><given-names>CS</given-names></name><name><surname>Griewank</surname><given-names>K</given-names></name><name><surname>Paschen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic evolution of T-cell resistance in the course of melanoma progression</article-title><source>Clinical Cancer Research</source><volume>20</volume><fpage>6593</fpage><lpage>6604</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0567</pub-id><pub-id pub-id-type="pmid">25294904</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Pieper</surname><given-names>N</given-names></name><name><surname>Heeke</surname><given-names>C</given-names></name><name><surname>Maltaner</surname><given-names>R</given-names></name><name><surname>Stadtler</surname><given-names>N</given-names></name><name><surname>Real</surname><given-names>B</given-names></name><name><surname>Bielefeld</surname><given-names>N</given-names></name><name><surname>Howe</surname><given-names>S</given-names></name><name><surname>Weide</surname><given-names>B</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Utikal</surname><given-names>J</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Klein-Hitpass</surname><given-names>L</given-names></name><name><surname>Zeschnigk</surname><given-names>M</given-names></name><name><surname>Westendorf</surname><given-names>AM</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>S</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Griewank</surname><given-names>KG</given-names></name><name><surname>Paschen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15440</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15440</pub-id><pub-id pub-id-type="pmid">28561041</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugie</surname><given-names>K</given-names></name><name><surname>Funaya</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>MG</given-names></name><name><surname>Aoki</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Expression of Dux family genes in early preimplantation embryos</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>19396</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-76538-9</pub-id><pub-id pub-id-type="pmid">33173118</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Tawbi</surname><given-names>HA</given-names></name><name><surname>Hernandez</surname><given-names>G</given-names></name><name><surname>Wongchenko</surname><given-names>MJ</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>L</given-names></name><name><surname>Ballinger</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Cha</surname><given-names>E</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients</article-title><source>Nature Medicine</source><volume>25</volume><fpage>929</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0474-7</pub-id><pub-id pub-id-type="pmid">31171876</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawbi</surname><given-names>HA</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Lipson</surname><given-names>EJ</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Matamala</surname><given-names>L</given-names></name><name><surname>Castillo Gutiérrez</surname><given-names>E</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Gogas</surname><given-names>HJ</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>De Menezes</surname><given-names>JJ</given-names></name><name><surname>Dalle</surname><given-names>S</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Abaskharoun</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>M</given-names></name><name><surname>Keidel</surname><given-names>S</given-names></name><name><surname>Simonsen</surname><given-names>KL</given-names></name><name><surname>Sobiesk</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma</article-title><source>The New England Journal of Medicine</source><volume>386</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2109970</pub-id><pub-id pub-id-type="pmid">34986285</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Grambsch</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2000">2000</year><source>Modeling Survival Data: Extending the Cox Model</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4757-3294-8</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Therneau</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>A package for survival analysis</data-title><version designator="3.4-0">3.4-0</version><source>R Package</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survival">https://CRAN.R-project.org/package=survival</ext-link></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title><source>Briefings in Bioinformatics</source><volume>14</volume><fpage>178</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id><pub-id pub-id-type="pmid">22517427</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TopHat: discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp120</pub-id><pub-id pub-id-type="pmid">19289445</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiddon</surname><given-names>JL</given-names></name><name><surname>Langford</surname><given-names>AT</given-names></name><name><surname>Wong</surname><given-names>CJ</given-names></name><name><surname>Zhong</surname><given-names>JW</given-names></name><name><surname>Tapscott</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conservation and innovation in the DUX4-family gene network</article-title><source>Nature Genetics</source><volume>49</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/ng.3846</pub-id><pub-id pub-id-type="pmid">28459454</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Ggplot2: elegant Graphics for data analysis</data-title><version designator="3.5.1">3.5.1</version><source>Tidyverse</source><ext-link ext-link-type="uri" xlink:href="https://ggplot2.tidyverse.org">https://ggplot2.tidyverse.org</ext-link></element-citation></ref><ref id="bib121"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>François</surname><given-names>R</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Müller</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>dplyr: A grammar of data manipulation</data-title><version designator="1.0.10">1.0.10</version><source>R Package</source><ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=dplyr">https://CRAN.R-project.org/package=dplyr</ext-link></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>Y</given-names></name><name><surname>Bartok</surname><given-names>O</given-names></name><name><surname>Patkar</surname><given-names>S</given-names></name><name><surname>Eli</surname><given-names>GB</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Litchfield</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name><name><surname>Jiménez-Sánchez</surname><given-names>A</given-names></name><name><surname>Trabish</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Karathia</surname><given-names>H</given-names></name><name><surname>Barnea</surname><given-names>E</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><name><surname>Cinnamon</surname><given-names>E</given-names></name><name><surname>Stein</surname><given-names>I</given-names></name><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Bitton</surname><given-names>L</given-names></name><name><surname>Pérez-Guijarro</surname><given-names>E</given-names></name><name><surname>Dubovik</surname><given-names>T</given-names></name><name><surname>Shen-Orr</surname><given-names>SS</given-names></name><name><surname>Miller</surname><given-names>ML</given-names></name><name><surname>Merlino</surname><given-names>G</given-names></name><name><surname>Levin</surname><given-names>Y</given-names></name><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Eisenbach</surname><given-names>L</given-names></name><name><surname>Admon</surname><given-names>A</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name><name><surname>Samuels</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>UVB-induced tumor heterogeneity diminishes immune response in melanoma</article-title><source>Cell</source><volume>179</volume><fpage>219</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.08.032</pub-id><pub-id pub-id-type="pmid">31522890</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title><source>Innovation</source><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Tsuzuki</surname><given-names>S</given-names></name><name><surname>Kawazu</surname><given-names>M</given-names></name><name><surname>Hayakawa</surname><given-names>F</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Imoto</surname><given-names>N</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name><name><surname>Kunita</surname><given-names>A</given-names></name><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Sakura</surname><given-names>T</given-names></name><name><surname>Yujiri</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>E</given-names></name><name><surname>Fujimaki</surname><given-names>K</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Aoyama</surname><given-names>Y</given-names></name><name><surname>Ohtake</surname><given-names>S</given-names></name><name><surname>Takita</surname><given-names>J</given-names></name><name><surname>Sai</surname><given-names>E</given-names></name><name><surname>Taniwaki</surname><given-names>M</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name><name><surname>Morishita</surname><given-names>S</given-names></name><name><surname>Fukayama</surname><given-names>M</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name><name><surname>Mano</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults</article-title><source>Nature Genetics</source><volume>48</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/ng.3535</pub-id><pub-id pub-id-type="pmid">27019113</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>A</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Kodaira</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>E</given-names></name><name><surname>Kawamoto</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Yoshimoto</surname><given-names>S</given-names></name><name><surname>Endo</surname><given-names>O</given-names></name><name><surname>Kodama</surname><given-names>N</given-names></name><name><surname>Kushima</surname><given-names>R</given-names></name><name><surname>Hiraoka</surname><given-names>N</given-names></name><name><surname>Motoi</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CIC-rearranged sarcomas: a study of 20 cases and comparisons with ewing sarcomas</article-title><source>The American Journal of Surgical Pathology</source><volume>40</volume><fpage>313</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000000570</pub-id><pub-id pub-id-type="pmid">26685084</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimoto</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>C</given-names></name><name><surname>Chilton-MacNeill</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Shago</surname><given-names>M</given-names></name><name><surname>Squire</surname><given-names>J</given-names></name><name><surname>Zielenska</surname><given-names>M</given-names></name><name><surname>Somers</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event</article-title><source>Cancer Genetics and Cytogenetics</source><volume>195</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2009.06.015</pub-id><pub-id pub-id-type="pmid">19837261</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>Omics</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaretsky</surname><given-names>JM</given-names></name><name><surname>Garcia-Diaz</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>DS</given-names></name><name><surname>Escuin-Ordinas</surname><given-names>H</given-names></name><name><surname>Hugo</surname><given-names>W</given-names></name><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Torrejon</surname><given-names>DY</given-names></name><name><surname>Abril-Rodriguez</surname><given-names>G</given-names></name><name><surname>Sandoval</surname><given-names>S</given-names></name><name><surname>Barthly</surname><given-names>L</given-names></name><name><surname>Saco</surname><given-names>J</given-names></name><name><surname>Homet Moreno</surname><given-names>B</given-names></name><name><surname>Mezzadra</surname><given-names>R</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Ruchalski</surname><given-names>K</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Sanchez</surname><given-names>PJ</given-names></name><name><surname>Puig-Saus</surname><given-names>C</given-names></name><name><surname>Cherry</surname><given-names>G</given-names></name><name><surname>Seja</surname><given-names>E</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Pang</surname><given-names>J</given-names></name><name><surname>Berent-Maoz</surname><given-names>B</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Schumacher</surname><given-names>TNM</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mutations associated with acquired resistance to PD-1 blockade in melanoma</article-title><source>The New England Journal of Medicine</source><volume>375</volume><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1604958</pub-id><pub-id pub-id-type="pmid">27433843</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity</article-title><source>Nature Immunology</source><volume>19</volume><fpage>723</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0132-0</pub-id><pub-id pub-id-type="pmid">29915296</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89017.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Linch</surname><given-names>Mark</given-names></name><role specific-use="editor">Reviewing Editor</role></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study presents a <bold>valuable</bold> finding on the association between DUX4 expression with features of immune evasion in human tissue and clinical outcomes in patients with advanced urothelial cancer. The evidence supporting the claims of the authors is <bold>convincing</bold>, using a range of corroborative statistical techniques. Compared to an earlier version, the quality of the manuscript has been enhanced, for example Figure 5 now illustrates the key features of survival probability estimates over time for patients assigned to with the test or training set.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89017.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Pineda et al investigate the association of the hypothesis that Dux4, an embryonic transcription factor, expression in tumor cells is associated with immune evasion and resistance to immunotherapy. They analyze existing cohorts of bulk RNAseq sequenced tumors across cancer types to identify Dux4 expression and association with survival. They find that Dux4 expression is detected in a higher proportion of metastatic tumors compared to primary tumors, is associated with decreased immune infiltrate and a variety of immune metrics and previously nominated immune signatures, and do an in depth evaluation of a cohort of metastatic urothelial cell carcinoma, finding that Dux4 expression is associated with a more immunodeficient tumor microenvironment (desert or excluded microenvironment) and worse survival in this aPDL1 treated cohort. They then find that Dux4 expression is a major independent predictor of survival in this cohort using different types of survival analyses (KM, Cox PH, and random survival forests). With prior existing biological data supporting the hypothesis (in prior work, the senior author has demonstrated Dux4 expression causally suppresses MHC-I expression in interferon-gamma treated cell lines), the current work links Dux4 expression with less immune activity in clinical tumor samples and with survival in ICI treated urothelial carcinomas, and demonstrates that Dux4 expression provides independent information towards survival including other molecular and clinical characteristics (TMB, ECOG PS as the other strongest markers), and provides interesting resolution on landmark analyses with TMB and Dux4 expression providing greater informativeness at later survival landmarks (e.g. 1 year and later), while ECOG PS has strong informativeness already at earlier time points. This work provides impetus towards more mechanistic and functional dissection of the mechanism of Dux4-associated changes with the tumor microenvironment (e.g. in vivo mouse studies) as well as potential interventional studies (e.g. Dux4 as a target in combination therapies). What the work does not provide is additional resolution on the mechanism of how Dux4 may be associated with a more immunodeficient microenvironment.</p><p>The conclusions are generally well supported, but there are issues that would benefit from clarification and extension:</p><p>- The finding that Dux4 expression is detected in a higher proportion of metastatic tumors and at higher levels compared to TCGA samples (Fig 1BC) is striking. However, at least for one tumor type (melanoma), the TCGA cohort is comprised of mostly locoregional metastatic (n=81 primary and 367 metastatic tumors in the PanCan Atlas). Since there are annotations for primary and (locoregional) metastatic samples in TCGA, an analysis of the primary vs. locoregional metastasis vs distant metastatic samples seems reasonable and likely informative. The analysis of tumors with matched FFPE and flash frozen samples with hybrid probe capture and polyA sequencing, respectively is a nice validation to show that the difference in Dux4 expression is not due to differences in preservation of starting material/sequencing in the metastatic samples vs TCGA samples (S1BC).</p><p>- The findings that Dux4 expression in the metastatic urothelial carcinoma setting is associated with a more immunodeficient microenvironment (Figure 2) is clear and unambiguous using multiple lines of data and analyses (bulk RNAseq, DUX4-positive vs DUX4-negative tumors, different immune cell and cytokine signatures; IHC showing an association with immune deserts and immune excluded phenotypes). However, this is an association and does not demonstrate causality.</p><p>- The survival analyses (Fig 3,4,5) show fairly convincingly that Dux4 provide independent predictive information beyond clinical variables and TMB towards survival in the aPDL1 treated metastatic urothelial carcinoma cohort. However, the choice to split the cohort into Dux4 negative (defined as &lt; 0.25 TPM) and Dux4 positive (&gt; 1 TPM) while excluding a large number of patients (n=126 pts) that fall in between has significant impact on the rigor of conclusions. This would benefit from showing all the data (e.g. including the 3rd group of in-betweens in the survival analyses as a separate group).</p><p>- The authors demonstrate that adding Dux4 to clinical markers and TMB results in an improved predictive model for survival, but there are a few questions regarding this model as a clinical biomarker</p><p>o Is Dux4 expression better than other correlated immune signatures/markers (e.g. interferon gamma, T effector signature, overall immune infiltrate) in providing additional information?</p><p>- The use of random survival forests to quantify the (predictive) marginal effect of Dux4+ vs Dux4- expression on survival in a non-parametric model as well as shed light on association with survival at different landmark times using Shapley values is quite interesting and well conducted.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89017.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This article takes an expansive look at the potential role of DUX4 in cancer treatment and prognosis, including its correlation with other key biomarkers, the potential for cancer to be resistant to treatment, and risk prediction.</p><p>Strengths:</p><p>The primary strength of this work is the breadth of the analyses. The authors have linked DUX4 to not just one but multiple points in the trajectory of cancer, which increases the face validity of their conclusion that DUX4 is meaningfully related to the course of a cancer as well as the prognosis for a patient.</p><p>Statistically, the authors have taken care to properly validate their findings using appropriate bootstrapping and testing strategies.</p><p>Weaknesses:</p><p>Several weaknesses are noted. First, there is little-to-no description of the underlying sample population. It is only stated that &quot;several large cohorts of patients with different metastatic cancers&quot; were analyzed, and that a cohort of patients with advanced urothelial cancer was used for estimating associations with clinical outcomes. Lacking is information on the sampling mechanism, inclusion/exclusion criteria, treatment modalities, the definition of 'time = 0', the number of events observed, or even the sample size. Knowledge about the underlying study design would help explain some counterintuitive results, e.g. that the hazard of death among patients with Stage IV cancer is half that of those with Stage I cancer (Table 1); presumably this is not because Stage IV is actually protective but rather an artifact of the sampling scheme for these data. Second, the definition of negative versus positive DUX4 expression varies throughout the paper. In Figure 2B, Figure 3A, and Figure 3C, it is defined as &gt;1 TPM vs. &lt;= 1 TPM; in Figure 4A and Figure 5A, it is defined as &gt;1 TPM vs. &lt; 0.25 TPM; in Figure S1C it is partitioned into four groups, with boundaries defined at 0.25 TPM, 1 TPM, and 5 TPM. If categorization is needed, a rationale should be provided (ideally prospectively and not based upon the observed data, so as to avoid the perception of forking paths analyses), and it should be consistently applied. Third and finally, data seem to be occasionally excluded without rationale. For example, as mentioned above, the Cox model presented in Figure 4A seems to exclude all patients with DUX4 TPM between 0.25 and 1. Figure 3C excludes patients with TMB in the lowest quartile (although the decision was ostensibly to control for TMB confounding, there are more appropriate ways to do so that don't result in loss of data, e.g. a stratified KM plot). Excluding patients based upon a particular region of the covariate space makes interpreting the resulting model awkward.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.89017.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pineda</surname><given-names>Jose Mario Bello</given-names></name><role specific-use="author">Author</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bradley</surname><given-names>Robert K</given-names></name><role specific-use="author">Author</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><addr-line><named-content content-type="city">Seattle</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1:</bold></p><p>Figure 1</p><list list-type="bullet"><list-item><p>The &quot;matched primary tumors&quot; from TCGA include n=424 from cutaneous melanoma; but it is unclear where this is coming from; the PanCan Atlas for melanoma shows n=81 primary and 367 metastatic tumors. There are also additional large cohorts of ICI-treated metastatic tumors with RNAseq data (e.g. a metastatic melanoma cohort with 100+ patients <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41591-019-0654-5">https://doi.org/10.1038/s41591-019-0654-5</ext-link>) that would increase the numbers here.</p></list-item></list></disp-quote><p>We thank the reviewer for their observation. We have replaced references to “primary” cancers as “TCGA” cancers as appropriate. While the TCGA analyses included metastatic samples, the majority of the TCGA tumors in most cohorts correspond to primary cancers or local metastases, a point which we added to the text. We retained Fig. 1D as the representative examples are actual primary samples. We have decided to defer analysis of additional melanoma cohorts for future inquiry.</p><disp-quote content-type="editor-comment"><p>Figure 2</p><list list-type="bullet"><list-item><p>What is the basis for the split between high and low Dux4 expressing tumors at 1 TPM? Is it arbitrary, or based on some structure in the distribution? (e.g. bimodal distribution)</p></list-item></list></disp-quote><p>Our previous analyses of RNA-seq datasets derived from early embryogenesis samples (PMID: 3132774, 28459457) showed that physiologic levels of DUX4 range from approximately 2 to 10 TPM. We added a description in the methods section, under “Genome annotations, gene expression, and Gene Ontology (GO) enrichment analyses,” of our conservative choice for the threshold: DUX4-positivity defined as expression levels &gt; 1 TPM.</p><disp-quote content-type="editor-comment"><p>Figure 3</p><list list-type="bullet"><list-item><p>Overall claim is that Dux4 expression is associated with worse survival in metastatic urothelial carcinomas treated with PD-L1 inhibitor. However, the rationale for the choice of split (Dux4 expression &lt; 0.5 and &gt; 1 TPM) to show is unclear (is this the 25th percentile? 75th percentiles?), and the rationale/interpretation of the &quot;partial adjustment&quot; for TMB by removing the bottom quartile of TMB feels non-rigorous and prone to bias. It doesn't feel like Fig 3bc contributes very much; Figure 4 really is the more rigorous analysis.</p></list-item></list></disp-quote><p>We thank the reviewer for these comments and suggestions. We adjusted the analyses in Fig. 3C and Fig. S3 to be consistent with Fig. 1 and Fig. 2, in terms of the choice of split. We also clarified in the text how our initial, crude TMB adjustment served as an important indication for us to pursue more rigorous statistical approaches.</p><disp-quote content-type="editor-comment"><p>Figure 4</p><list list-type="bullet"><list-item><p>Dux4 expression is independently associated with worse survival considering other clinical and molecular characteristics</p></list-item></list><list list-type="bullet"><list-item><p>I would include TGFB in the features considered in the table (in the supplementary but not the main table or forest plots, not sure why not?)</p></list-item></list><list list-type="bullet"><list-item><p>The choice of Dux4 expression split ( &lt; 0.25 and &gt; 1 TPM) feels arbitrary and is different than the split in Figure 3; what is the rationale for this? Also, how many patients does this exclude? (TPM between 0.25 and 1). What does the continuous value or median split for Dux4 expression give you for the CoxPH model?</p></list-item></list><list list-type="bullet"><list-item><p>Re: building a predictive model, excluding patients (e.g. between &lt;0.25 and &gt; 1 Dux4 TPM) makes the model difficult to apply (e.g. cannot apply to patients with Dux4 levels in the missing interval); a better predictive model would include all patients in the cohort.</p></list-item></list></disp-quote><p>We thank the reviewer for their other suggestions. We have clarified in the text that our choice to define DUX4negative samples as those with DUX4 expression levels &lt; 0.25 TPM was made to preemptively address potential misclassifications due to decreased sensitivity of bulk RNA-seq at very low expression levels (PMID: 18516045). We believe our classifications with the new scheme are more reliable. We have also now specified in the text that our categorization excludes 126 patients. We have decided to not pursue the addition of TGFB or exploration of the use of an alternative split or continuous version of DUX4 expression in the Cox Proportional Hazards analyses but appreciate the suggestions, which we will keep in mind for future studies.</p><disp-quote content-type="editor-comment"><p>Figure 5</p><list list-type="bullet"><list-item><p>An RSF (randomized survival forest) model predicts survival in Dux4+ vs Dux4- patient, and the Shapley values for landmark time analyses show time-varying effects of different features.</p></list-item></list><list list-type="bullet"><list-item><p>In some sense, the authors have already demonstrated that Dux4+ is associated with survival differences in ICI treated patients; so a model that predicts survival applied to Dux4+ and Dux4- patients that shows a difference in survival is unsurprising (even in a training/test set setting given that there is a difference in survival across the entire cohort). The quantified marginal effect (from a predictive perspective) of different features is what is interesting here. In that light, I'd like to see more validation of the model up front, specifically how close the predicted survival is to the actual survival of patients (e.g. the survival curves in Fig 5a but with actual survival of the Dux4- and Dux4+ cohorts superimposed on the predicted probabilities).</p></list-item></list></disp-quote><p>We thank the reviewer for this suggestion. We have added a plot showing the superimposed survival probability estimates over time for the RSF and KM models for patients assigned to either the test or training sets in Fig. 5.</p><disp-quote content-type="editor-comment"><p>SFig 5</p><list list-type="bullet"><list-item><p>Unclear how the authors got estimates of the # of expected deaths associated with covariates (e.g. &quot;...we measured an increase in the number of predicted deaths associated with DUX4-positivity by approximately 16, over DUX4negative status (Fig S5F-G).&quot;) from Shapley values as shown in the indicated figure - is this 16 out of the entire cohort? At a given time point? Would recommend perhaps showing the inferred absolute change in mortality (e.g. 8% absolute increase in mortality)</p></list-item></list></disp-quote><p>Mortality is the expected number of deaths for the cohort over the observation window, measured as the sum of the CHF over time. We have clarified this in the Methods section, under “Random Survival Forest, feature importance, and partial dependence.” We have also changed the quantification to show the absolute mortality differences comparing patients with DUX4-negative and -positive tumors; we thank the reviewer for this suggestion. We have also clarified in the text that adjusted mortality was estimated via partial dependence, which operates using the correct units, as opposed to Shapley values, where attribution is scaled. Finally, we changed the referenced figure when discussing changes in mortality associated with TMB and DUX4 status (Fig. S5H-I); we appreciate the reviewer pointing out this error.</p><disp-quote content-type="editor-comment"><p>Figure S1B-C</p><list list-type="bullet"><list-item><p>The authors argue that Dux4 expression is not an artifact of FFPE tissue by analyzing a mixed tumor cohort sequenced with both poly-A and hybrid probe capture in matched flash-frozen and FFPE tumor samples, showing that it is (1) detectible both FFPE and flash-frozen tissue and (2) higher levels are detected in polyA sequencing/frozen tissue. However, the reference for this section (D. Robinson et al 2015) is a study of a cohort of prostate cancers with polyA bulk RNAseq sequencing; is this correct/is the data coming from a different study?</p></list-item></list><list list-type="bullet"><list-item><p>Analysis of scRNAseq (if available) would strengthen their analyses by better delineating the expression and response of interferon-gamma and downstream (e.g. antigen presentation) pathways in specific cell compartments, and potential differences in cell-cell interactions (e.g. using CellPhoneDB) associated with Dux4+ vs Dux4- tumors.</p></list-item></list><list list-type="bullet"><list-item><p>Do the investigators find similar findings in primary and metastatic tumors sequenced the same way (e.g. tcga primary vs met melanoma, albeit most of the met melanoma are Stage III lymph nodes)?</p></list-item></list></disp-quote><p>We thank the reviewer for finding the citation error. We have corrected the manuscript to reflect the correct study we analyzed (PMID: 28783718). We also thank the reviewer for their additional suggestions, which undoubtedly would strengthen the current study. However, we have respectfully decided to defer these additional analyses for future study.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2:</bold></p><p>It is strange as a statistician to see BIC and AIC represented as barplots, e.g. Figure 4B. There is no knowledge to be gained through this visual representation that would not otherwise be conveyed by just giving the numbers.</p></disp-quote><p>We thank the reviewer for this suggestion. We understand that simply stating the numbers would be equally informative. However, we respectfully decided to retain our current versions of Figures 4 and S4 so that the numbers can be illustrated in a visual manner in the figures, rather than just stated in the text.</p></body></sub-article></article>